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Preface  
 
A brief history of breast cancer treatment, diagnostics and research 
Tumors in the breast was described as early as on papyrus from ancient Egypt (3000-
2500 BC) but until the 19th century the only treatment offered women with breast 
carcinoma was high risk surgery. The 19th century reformed the diagnostics and treatment 
of cancer in general as both anesthetics and antiseptic surgery was introduced. In 1895 
Wilhelm von Roentgen discovers the x-rays, which in 1899 is reported to be used to cure 
a cancer patient. Marie and Pierre Curies discovery of the radioactive element Radium in 
1898 was later of major importance in cancer treatment. At both sides of the Atlantic, 
radical mastectomy was introduced and further developed by Charles Moore, William 
banks and William Halsted. There were debates concerning the type of surgery; some 
claimed that women’s ribs should be removed while others tried to minimize the surgery 
and instead combine the treatment with radiation. Other important debates were whether 
tumor cells spread through lymph- or blood vessels. The treatment of breast cancer made 
a shift during the fifties with the introduction of chemotherapy, and in the following 
decades both the combination strategy and adjuvant chemotherapy were major 
breakthroughs in breast cancer treatment. At the same time, as the results from 
independent randomized trials lead by Veronesi and Fisher were published, breast 
conserving surgical techniques were favored. The development of lymph node 
mapping/sentinel node biopsy technique led to less extensive axillary surgery, reducing 
the negative side effects of surgery for women without lymph node involvement. 
The pathologist Rudolph Virchow (1821-1902) was crucial in the development of 
microscopic examination of tissue and in defining cellular pathology as a medical 
discipline. He demonstrated that cancer rises from collections of diseased cells, and is 
known for his statement “omnis cellula e cellula” meaning that every cell has risen from 
another cell. Von Hansemann and Boveri were crucial for the discovery of chromosomes 
being the seats of cell hereditary and for describing the disruption of these highly 
organized structures in cancer cells. In 1925 Greenough proposed that breast cancer is 
more than one disease, and from survival data he deduce that there are three different 
classes of malignancy. In 1957 the Bloom and Richardson grading was published, a 
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modified form of this is the histological grading system used today. Steinthals division of 
tumors into stages (later developed by Denoix (the TNM classification) was a significant 
improvement in preoperative assessment, and a modified version is used today combining 
pathology and clinical information to guide treatment choices for the individual patient. 
A major contribution to the improved outcome of the disease is the introduction of 
systemic adjuvant treatment and radiotherapy.  The discovery of the effect of removing 
the ovaries on breast cancer growth was published in 1896 by George Beatson, but 
estrogen was first discovered in 1925 in urine from pregnant women, and estrogen 
receptor (ER) was frequently found in breast carcinomas. Tamoxifen (a drug proposed to 
have anti estrogen effect) was first used as a treatment for breast cancer in 1969, and the 
largest effect was seen in postmenopausale women. Brodie discovered in 1982 that a 
known aromataseinhibitor could stop tumor growth. In 1995 Gustafsson discovered a 
second estrogen receptor and the dual effect on hormone receptor therapy get more 
evident leading to the concept “SERMs”, selective estrogen receptor modulators. In 1965 
started Nissen Meyer the first multicentre trial with cyclophosfamide and showed an 
increased survival rate. This was followed by several studies showing a survival benefit 
for the combination regimen of cyclophosfamide, metotrexate and 5-fluorouracil (CMF). 
There have been performed several large scaled clinical trials addressing the effect of 
adjuvant systemic treatment on breast cancer. Furthermore, the results of these studies 
have also been registered in the European Breast Cancer Trialist Collaborative Group 
(EBCTCG). Analysis of these pooled data with a high number of individuals with long 
clinical follow up provide a strong basis for developing guidelines for evidence based 
clinical treatment of this complex and important patient population. Adjuvant treatment is 
now evolving rapidly with more drugs to choose from. Therapy targeted to a specific 
molecule is proposed to be the next revolution in cancer treatment; it makes it possible to 
tailor the choice of therapy for each woman aiming at getting maximum effect with a 
minimum of side effects. One example of this approach is Trastuzumab, the HER2 
receptor binding drug that has been introduced to women whose tumors have increased 
number of the receptor. The research focusing on molecular alterations in breast 
carcinomas have been enormous. In 1979 the tumor protein 53 (TP53) was identified by 
Levine, Lane and Old and the gene was cloned in 1983. One year later the human 
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epidermal growth factor receptor EGFR was discovered and in the following year human 
epidermal growth factor receptor 2 (HER2/neu/erbB2) by Weinberg. The breast cancer 
gene 1 and 2 (BRCA1 and BRCA2) was discovered by Skolnic in 1994 and by Stratton in 
1995 respectively, pinpointing genomic alterations explaining a fraction of hereditary 
breast cancer.  
Mammography used for early detection of breast cancer at an early phase was 
introduced a century ago, but was systemized first in 1963 by Shapiro and Strax. This 
was followed by several studies of mammography as screening of healthy individuals 
confirming the advantages in increased survival among patients detected by 
mammography. The official advice in Norway is now mammography screening of all 
females in the age group 50-69 years.  
The focus on women’s physical but also psychological condition after breast 
cancer diagnosis and treatment became more in focus during the 70’s and 80’s. It is 
fascinating to see the historical shift in the perception of this “common” disease. New 
knowledge and improved techniques have made it possible to move from the conception 
of breast cancer as “one disease-one treatment” to the more ominous view that both 
patient related factors such as age, tumor characteristics (such as molecular alterations) 
and clinical findings must all be taken into consideration to tailor the therapy. The last 
decade’s research performed on large national and international trials testing new drugs, 
combination of drugs or drugs tailored to selected groups of patients show promising 
results As will be discussed later in this thesis, the introduction of high resolution 
methods such as microarrays and more recently deep-sequencing has increased the 
knowledge of molecular alterations in breast cancer enormously. More detailed 
diagnostics are already making attribution to the clinical decision making, and this will 
continue resulting in better disease control and less side effect of treatment for the 
individual woman. 
 
(Sources; Brystkreft- diagnostikk og behandling; Novartisserien, faghefte nr. 12, 2007, The history of 
Breast Cancer; Breast Cancer Campaign, London 2009 and Weinberg RA, In retrospect: The chromosome 
trail, Nature 453, 725, 2008)  
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General Introduction  
 
Classification aims at defining groups of distinct entities and to specify a relationship 
between them. Scientific taxonomy is applied to several disciplines including cancer 
biology. To date the classification of breast carcinomas are based on morphological 
criteria and molecular analyses applied in breast cancer diagnostics have been of 
prognostic or predictive value. This study has been focusing on identifying robust 
subgroups of breast cancer by analyzing multiple different features in breast tumors. The 
conclusions from the four separate studies presented in this thesis add knowledge about 
breast cancer subtypes and tumor progression and are presented and discussed together 
with a review of other studies in the field. The advantages and limitations of the materials 
and methods used are discussed separately after a summary of each paper.  
 
Epidemiology 
 
Incidence and risk factors 
The incidence of female breast cancer varies worldwide and is markedly higher in high 
income countries such as North America and Western Europe1. Breast cancer is rarely 
diagnosed before age 30 but risk increases with age, and BC is the most frequent 
diagnosed cancer in women in Norway (2761 new cases in 2007) and has the highest 
cumulative risk with about 1:12 women diagnosed with breast cancer during lifetime2. 
The incidence has been and is still increasing, this is considered both as a result of 
demographic changes (population growth and ageing), increased ability to diagnose the 
disease and mass screening but also reflects a real increase in risk2, 3. 
Breast cancer is partly a hormone related disease, the most important risk factors 
being early menarche, low parity, late age at first pregnancy, late menopause and 
hormonal exposure4. More recently ageing is also considered a major risk factor1. Age 
specific incidence of breast cancer shows a plateau midlife termed Clemmesen’s hook, 
often attributed to menopause5. Another interpretation of this phenomenon is that the 
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incidence curve reflects two major types of breast cancer; one ER negative, early onset 
type and one ER positive with late onset.  
 
Figure 1: The barchart to the left illustrates that breast cancer has the highest incidence among Norwegian 
women (2003-2007). The graph to the right show the increase in incidence seen in the period 1953-
2007(From The Norwegian Cancer Registery2) 
 
Bilateral breast cancer is rare and accounts for approximately 5% of breast cancer 
cases, and women with bilateral disease have a higher mortality than women with 
unilateral disease6. The incidence of bilateral disease diagnosed at the same time or 
within a short time span (synchronous disease) is increasing, while the incidence of 
bilateral tumors with a longer time span (metachronous disease) is decreasing6. This is 
probably reflecting the effect of increased use of adjuvant therapy; it having a preventive 
effect on developing contralateral disease. Daughters of mothers with bilateral disease 
have a higher risk of breast cancer7 reflecting a hereditary component in bilateral disease. 
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Breast cancer in patients with either a strong family history of breast cancer or harboring 
a germline defect in high penetrance cancer susceptibility genes such as BRCA1, BRCA2, 
TP53, PTEN and ATM are defined as hereditary breast cancer and is estimated to be 
contributing up to 10% of all cases4.  
 
Mortality 
Breast cancer is the major cause of death among adult women in high income countries 
but in Norway, the risk of dying of the disease seems to decline3. Both the incidence and 
survival was found to be increasing rapidly in Norway during the 1990’s, partially 
because of the introduction of mass screening and increased use of adjuvant therapy 8. 
The 15 year survival is slightly above 70%, but markedly less for the lower and higher 
age groups (<30 and >75 years).  Survival increases to 90% given they survive 5 years, 
but the long term cumulative survival continues to decline many years after diagnosis3.  
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Anatomy and histology of the breast gland 
 
The breast gland 
The female breast, serving the important function of producing and providing milk to our 
offspring, has a dynamic response to the changing hormonal phases during a woman’s 
lifetime. Prepubertal breasts have rudimentary glandular structures, which during the 
extreme hormonal changes during puberty develops into 15-20 lobes that terminate into 
separate openings in the nipple (Fig. 2). Every lobe has a branching network of ducts 
draining smaller units called lobules, each composed of smaller secretory units called 
alveoli. This unit is called TDLU (terminal ductal-lobular unit) and is considered the 
functional unit of the breast. Both the amount of glandular structures and the surrounding 
fibro-adipose tissue are dependent on the hormonal status (menstrual cycle, pregnancy, 
lactating-, premenopausal- and postmenopausal state). The final differentiation stage is 
achieved during pregnancy and lactation by the formation of lobulo-acinar structures.  
The breast epithelium is two layered surrounded by a basement membrane. The 
outer layer is composed of contractile myoepithelial cells and the inner layer of polarized, 
luminal cells where some have exocrine properties (Fig. 3B). 
 
 
 
 
 
 
Figure 2:  
Left: The changes of the female breast during puberty with development of lobes with ducts and lobules. 
Middle:The branching network of ducts draining the lobules surrounded by tissue rich in fat. From 
Netter/Elsevier. 
Right: An illustration of the organization of the two main celltypes in a duct. 
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The hierarchy of breast epithelial cells 
In hematology, the knowledge about hierarchical relationship between stem cells and 
mature cells of different lineages have been acknowledge for some time9, but for the cell 
types in the breast such relationship has just started to emerge10. The hierarchical 
relationship was suspected more than a decade ago as cells with specific combinations of 
cytokeratins was found by IHC in fetal and infant breasts11. The dynamic properties of 
breast epithelium demand compartments of stem cells and progenitor cells; i.e. cells with 
high proliferation potential and ability to differentiate. They reside in a protective and 
highly controlled region called the stem cell niche, and it seems evident that this is 
located in the TDLU regions10, 12, 13. The main cell-types, luminal and myoepithelial cells, 
likely represent mature cells from separate lineages but originating from the same stem 
cell and bipotent progenitor as is illustrated in Figur 314-16. 
 
Figure 3: 
A: An illustration of the assumed hierarchy of breast epithelial cells reflecting the relationship between the 
stem cell, the various progeny and the major mature cells.  
B: The stem cell and the bipotent progenitors reside in the TDLU area while the more differentiated cells 
are residing either in the basal layer (myoepithelial cells) or the inner, duct-lining layer (luminal epithelial 
cells). From Polyak 200715. 
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A stem cell has the ability to self renew and to generate more specialized cells by 
differentiation. This is stepwise, where the first (and less differentiated) offspring are 
called progenitor cells. These cells have lost the capacity to self-renew, but are rapid 
proliferating cells capable to give rise to more differentiated cells needed as a response to 
external signals due to puberty, pregnancy or other demands. As indicated in Figure 3, 
several molecular markers seem to identify cells at different stages, but as the hierarchy 
probably is much more complex than the one exemplified, there are to be expected that 
this will change15. 
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Morphological classification of breast cancer 
 
Invasive carcinoma 
Microscopic examination of BC reveals heterogeneity both at the architectonical and the 
cellular level17. The compositions of carcinomas can range from stroma rich tumors with 
glandular structures of tumor cells with minimal atypia to solid growth of large, highly 
atypic carcinoma cells. Breast carcinomas are commonly classified according to the 
World Health Organization’s (WHO) recommendations17. The dominating growth pattern 
determines the type; this way a tumor with predominant tubular differentiation will be 
recognized as a distinct entity as will a tumor with either apocrine, lobular, cribriform, 
mucinous, medullary features etc. Such tumors are called ‘special types’, and WHO 
recognizes 18 different types (Fig. 4). Of the special types lobular carcinomas are most 
common (10-15%) while others are extremely rare (<1%). The most frequent histological 
type is ductal carcinomas (‘invasive ductal carcinoma not otherwise specified (NOS)’)17. 
Ductal carcinomas are a heterogeneous group of tumors that do not have sufficient 
characteristics of either of the special differentiation patterns to fall into any of those 
groups. Several of the rare subgroups have different clinical course and outcome17, 18. 
Mixed types are common and histological type has no major part in the Norwegian 
treatment guidelines to date.  
 
Figure 4: Left: Illustration of a of stroma rich ductal carcinoma with high differentiation, to the right a 
solid growing high grade invasive ductal carcinoma (HEx20) 
 
20 
 
Preinvasive neoplasia 
Among intraductal proliferative lesions, WHO recognizes usual ductal hyperplasia, flat 
epithelial atypia and atypical ductal hyperplasia in addition to ductal and lobular 
carcinoma in situ (DCIS and LCIS). The relationship between such lesions and invasive 
carcinoma is much debated and will be further discussed later in this thesis. The DCIS 
and LCIS are heterogeneous entities. This is reflected in the grading system used for 
DCIS; low grade DCIS have cells with only subtle atypia and distinct architectural 
features in contrast to high grade DCIS having highly atypic cells without orientation 
often with a solid growth pattern and necroses17.  
 
 
Prognostic and predictive markers in breast carcinomas 
 
A vast number of predictive and/or prognostic factors have been proposed for BC. Some 
factors are strictly prognostic (i.e. predicting the risk of recurrence and/or death from 
disease), predictive (predicts the likelihood of response to a given therapy) and others are 
both prognostic and predictive. The most established markers are histological grade, stage 
(size, lymph node involvement and metastases), steroid receptors, HER2, age at diagnosis 
and vascular invasion17, 19.  
 
Histological grade 
Various systems for grading aggressiveness based on histopathological assessment of 
differentiation pattern (luminal/glandular) and nuclear features have been developed. 
Bloom et al. presented one system in 195020, 21, this has been the fundament for the 
grading system used today; “the Nottingham modification of the Bloom and Richardson 
method” which was introduced in 199122. The degree of luminal differentiation, nuclear 
atypia/pleomorphism and mitotic index is combined in a single numerical score called 
histological grade. Each factor is assessed separately by examination of histological 
sections, given a numeric value (1-3) which is added into a score from 3-9. Tumors of 
grade 1 (score 3-5) have cells with tubular differentiation, few mitoses and lack of 
pleomorphia, this in contrast to grade 3 tumors (score 8-9) which are poorly 
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differentiated, have high mitotic index and are often highly pleoemorphic. Although 
histological grade is an independent prognostic index22, the major difference in outcome 
is seen by comparing Grade 1 to Grade 3 tumors.  This was the focus of the study by 
Sotiriou et al. defining genes able to subdivide grade 2 tumors into two groups with better 
and worse outcome23. That a binary grading of DCIS based on molecular observation 
improve the clinical evaluation is supported by others24. 
 
Staging of the disease 
Both the size of the tumor and nodal involvement (i.e. metastases in regional 
lymphnodes) has independent prognostic value25. These two factors are positively 
correlated, but tumors size is found to be more important in lymph node positive patients 
than in negative26. Both tumor size and lymphnode involvement are, in addition to 
metastases, used for staging a womans disease. Staging of breast cancer follow the 
guidelines from The European and the American cancer unions (UICC (Union Contre le 
Cancer) and AJCC (American Joint Committee on Cancer))27 and is based on the TNM 
classification28. The combined information of tumor size, nodal involvement and distant 
metastases will define the disease stage of each individual from, Stage I-Stage IV, each 
with different prognostic profiles (Fig. 5).   
A widely used system integrating size, lymph node metastases and grade is the 
Nottingham Prognostic Index (NPI), a numerical categorization stratifying patients into 
three prognostic groups29. The NPI is not in clinical use in Norway today. 
 
Figure 5: Breast cancer by stage. Left: trends in 5-year relative survival by stage show an increase in 
survival for patients with stage I, II and also II during the last two decades. Right: The long term relative 
survival by stage show a huge variation from stage I to IV. From Småstuen et al.3. 
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Other prognostic or predictive parameters 
The steroid receptors, ER and PgR, have predictive and a medium to weak prognostic 
value30-32. Stimulation of ER increase mitogen activity and induce expression of PgR33. 
The most widely used technique to measure ER and PgR protein expression is by 
immunohistochemistry (IHC). The advantage is that visual evaluation confirms that 
normal glandular epithelium in the biopsy do not cause false positive results, and the 
number and intensity of stained cells can be quantified in a semi-quantitative way. The 
major disadvantages are the use of different antibodies, detection systems and protocols 
causing inter-laboratory differences, so participation in quality assessment programs are 
of major importance. HER2/erbB2/neu is a protein with thyrosine kinase activity 
involved in regulation of cellular growth and is regarded as a prognostic and predictive 
factor in breast cancer (for review; 34). 
 
Gene expression signatures 
In the last decade several gene expression studies have defined groups of genes that 
subdivide breast carcinomas into different prognostic groups, regardless of 
histopathological classification, and several are commercialized (for review;35, 36). 
Among the first microarray based studies were the identification of ‘the intrinsic 
subtypes’37, ‘the 70-gene metastasis predictive signature’38, 39 and the ‘wound healing 
signature’40. Others have used PCR based techniques to identify responders and non 
responders to Tamoxifen 41. Two of the gene lists are forming the basis for large 
prospective studies (MINDACT and TAILORx). Such studies are useful to identify 
responders and non-responders to existing therapeutic regimen, but few have per se an 
approach aiming at classification of breast carcinomas. 
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Diagnosis and Treatment 
 
In Norway, NBCG defines and updates guidelines for diagnosis and treatment of breast 
cancer (Norsk Bryst Cancer Gruppe, NBCG; http://www.nbcg.no/nbcg.blaaboka.html). 
Tumors recognized as cancer will undergo histopathological examination including 
classification into histological type, histological grade and estimation of the size of the 
tumor. Lymphnodes will be carefully investigated to detect micro- or macro metastases. 
Only ER, PgR and HER2 status are molecular markers with predictive or prognostic 
value included in the national guidelines today.  
Breast cancer is today with a multi-disciplinary approach (NBCG guidelines). The 
cornerstone of all curative breast cancer management is surgical removal of the primary 
tumor with either breast conserving surgical technique or surgical removal of the whole 
breast and removal of lymph nodes, either by sentinel node biopsy or axillary lymph node 
dissection. Locally advanced-primarily inoperable tumors will often be offered neo-
adjuvant chemotherapy. Post operative radiation to the breast is offered all women with 
breast conserving surgery and no lymph node involvement and to women where 
histopathology showed positive or marginal distance to resection margin. Post operative 
radiation involving regional lymph node areas is offered individuals with positive lymph 
nodes depending on age and number of positive lymph nodes. Adjuvant systemic 
treatment is based on the use of both prognostic and predictive markers to all women with 
node positive disease and women with node negative disease depending on age, size, 
grade and HER2 and ER/PgR status. Women with hormone receptor positive disease will 
be offered 5 years of adjuvant endocrine treatment. The basis of adjuvant chemotherapy 
regimen is anthracyclins, and in Norway the standard regimen now is the FEC 
(Fluorouracil, epirubicin, cyclofosfamide) regimen. The benefit of taxanes has been 
studied the later years and the best effect is observed in lymph node positive disease and 
estrogen receptor negative disease. It is today standard treatment combined with FEC in 
these patients groups aged below 70.  HER2 positivity is usually associated with more 
aggressive clinical behavior. The monoclonal antibody Trastuzumab blocks the activity in 
the receptors tyrosine kinase and is now a part of the standard adjuvant treatment in 
individuals with HER2 positive tumors. For women with distant metastasis at the time of 
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diagnosis or distant disease relapse after primary treatment, the treatment will be 
palliative. Endocrine therapy, chemotherapy, Trastuzumab and local radiotherapy are all 
possible options to consider.  
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Why Classifiy? Review and discussion 
 
Grouping of tumors into classes or entities is of importance for several reasons. In 
clinical management, categorization of tumors is a tool to decide or standardize treatment 
and patients care. In a classification distinct entities should be recognizable in an 
objective way. The traditional way of constructing taxonomy in biology is by using a tree 
based approach where major classes can have smaller subgroups. A robust and objective 
classification is of importance when performing large clinical studies where clinical 
behavior and response to therapy are evaluated in order to standardize or tailor therapy. In 
haematopoietic and lymphoid neoplasia the classification has shifted from being 
descriptive to an integrative approach also including molecular alterations with features 
from the hierarchical relationship between mature haematopoietic cells, their progenity 
cells and stem cells. The knowledge about different lineages and molecular mechanisms 
determining the direction of differentiation have been the backbone for the modern 
classification of leukemias and lymphomas9, 42. As the hierarchical relationship between 
the epithelial cell-types of the breast have become more recognized, it is tempting to 
speculate that the same approach can be used to modernize breast cancer classification. In 
a Darwinian way of thinking, tree based taxonomy is not a static hierarchy. Offspring will 
show alterations in a progressive way leading to diversity. The time course of such 
progression has for mammals been millions of years, but a tumor with rapid growth will 
produce several levels of offspring during months or even weeks. If the daughter cells 
have acquired new characteristics compared to the parent cell, this can be defined as 
progression. Breast tumors in humans are recognized clinically at different stages of 
progression. One challenge in building a classification based on molecular alterations is 
that little is know about which lineages exist and at which stage or along which linage 
breast tumors develop. Whether tumors follow one path of progression or several, or 
which alterations characterize the different levels of progression still remains to be 
defined. To be able to relate findings of molecular subtypes to this, a review over tumor 
initiation and progression will be given.  
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Initiation and progression by successive genetic changes 
Cancer being caused by alterations in hereditary material was suspect before the 
discovery of DNA43, and genomic instability was shown decades ago to be a hallmark of 
cancer44. At that time it was acknowledge that transformation of cells into neoplasia 
required only a limited number of genomic changes45. This was also the main focus of the 
review by Hanahan and Weinberg46 defining different characteristics being essential for 
cancer development. Reflecting the enormous increase in knowledge in this field just in 
the last decade, a recent publication defines even more ‘hallmarks of cancers’47. The 
underlying defects of these hallmarks can prove to be important targets for treatment, but 
represent a complexity not captured by the standard classifications of today. As reviewed 
by Stratton et al., cancer can be considered an evolutionary process analogous to 
Darwinian evolution48. Two main processes are required; continuous acquisition of 
heritable genetic variation in individual cells and natural selection of cells with higher 
capability to proliferate and survive. If a single cell get sufficient advantageous 
alterations and reside in an environment providing ‘matching’ conditions, the result can 
be a tumor progressing into cancer. This is reflecting the heterotypic view on tumor 
formation and progression in contrast to the reductionist view46. The first focus on the 
fact that tumors are composed of other cell types such as endothelial cells, fibroblast, 
lymphatic cells etc. as well, but in the reductionist view the alterations in the tumor cells 
are the only ones considered. Normal development of the breast are dependent on stimuli 
from the environment and that tumor cells collaborate with or dictate other cells to 
provide an advantageous micro-environment is continuously more recognized49-51.  
Studies of rodent breast tumor development and progression as reviewed by 
Foulds in 1954 revealed some interesting features52. Spontaneous mammary tumors in 
rabbits begin either as adenomas in otherwise normal breast or in breast with cystic 
disease. The progression follows successive stages through non-invasive to invasive 
tumor and eventually to metastatic disease. Foulds concluded that cancer is the final step 
in a developmental process where the early neoplasia is not an invasive disease (i.e. 
cancer) either in structure or behavior. In studies of mice strain developing multiple 
tumors at the same time, the effect of host related factors on tumor progression could be 
studied. The breast tumors seemed to be of two types; ‘unresponsive’ tumors where 
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growth did not depend on hormonal related factors and ‘responsive’ tumors where the 
tumor growth was related to the hormonal state of the host. The studies showed that 
progression of one tumor was independent of other tumors and probably reflected a 
regulation by ‘intrinsic’ properties. Fould made six statements concerning tumor 
progression: 
 
These statements were based on observations from rodent experiments performed in the 
same decade the structure and composition of DNA were revealed, and therefore without 
any of the knowledge we have today about genomic related alterations in tumors. Much 
of the knowledge we have about molecular subclasses in breast carcinomas are based on 
clinical samples, and knowing that such samples are analyzed at individual progression 
levels, Foulds hypotheses can serve as a backbone for discussing the molecular types of  
breast carcinomas. 
 
Genomic data indicate at least two types of breast cancer 
Several studies analyzing genomewide DNA alterations have tried to identify groups of 
tumor with distinct features. Four different patterns of alterations were identified by 
Hicks et al. with high resolution aCGH analyses of two breast tumor cohorts53. The 
‘Simplex’ pattern had broad segments of duplications and deletions. Deletion of 16q, 8p 
and 22 as well as gain of 1q, 8q and 16p was dominating. ‘Complex I’ had either a 
“sawtooth” appearance with narrow segments of deletions and duplications affecting 
more or less all chromosomes. ‘Complex II’ resembled the ‘simplex’ but had at least one 
localized region of clustered peaks of amplifications called ‘firestorm’. The fourth pattern 
was called “flat” defining profiles with no clear gains or losses except from copy number 
1. Tumors progress independently 
2. Characters such as growth rate, responsiveness, invasiveness and the ability to 
disseminate are independent of each other. 
3. Progression is independent of growth rate 
4. Progression is continuous or discontinuous by gradual change or by abrupt 
steps 
5. Progression follows one of alternative paths of development, but can change 
course into a different path  
6. Progression does not always reach an end-point within the life-span of the host 
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polymorphism. Interestingly, all four patterns were found both in diploid and aneuploid 
tumors. The same groups have been identified in other datasets54. A study by Chin et al. 
using aCGH identified three subtypes of breast carcinomas that varied with respect to 
level of genomic instability55. The groups had overlapping characteristics with the classes 
in Hicks’ work. One group of tumors had few alterations and was dominated by 1q 
amplification and 16q deletion (the 1q/16q group), another group had more complex 
alterations (complex group), and the third displayed frequently high level amplifications 
(mixed amplifier group). Tumors with BRCA1 mutation had similar changes as the 
complex group. In this cohort it was also observed that shorter telomeres were associated 
with greater number of amplifications56, 57. Several studies have had quite divergent 
definitions on which genomic alterations characterize distinct subgroups of breast 
carcinomas, but that 1q and 16q alterations dominate in one type and multiple alterations 
on several arms dominate another are found by most58-64. 
 
Genomic changes in early stages of breast carcinogenesis 
The in situ breast carcinoma, DCIS, considered as a true precursor to invasive ductal 
carcinoma, is a heterogeneous group probably reflecting multiple types of breast 
tumors65-67. The loss of 16q is frequently found in DCIS, but also in proliferative and 
premalignant lesions such as usual ductal hyperplasia, columnar cell lesions, atypical 
ductal hyperplasia and in a substantial proportion of invasive carcinomas (ILC and also 
IDC), often in combination with 1q gain68-76. Low grade DCIS frequently display loss of 
16q and gain of 1q, while high grade DCIS have more alterations including high level 
amplifications of 6q22, 8q22, 11q13, 17q12 and 17q22-24 54, 65, 77, 78. The few CGH data 
that exists from LCIS are showing overall less gains than invasive carcinoma, and that the 
alterations partly overlap with grade I invasive carcinomas 66, 79, 80. In invasive tumors, 
deletion of 16q is more frequent a physical loss of the whole arm in grade I tumors, while 
alterations of 16q in grade II and grade III are more complex78, 81-83. Grade I tumors have 
fewer genomic alterations compared to grade III carcinomas that often have numerous 
genomic changes with chromosome arms 8q, 17q and/or 20q frequently altered84.  
Molecular studies of near-diploid invasive tumors probably give insight into early 
genomic changes in tumor progression. The most frequent rearrangements seen in such 
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cases by karyotyping are unbalanced translocations where a majority resulted in loss of 
one of the derivative chromosomes85, 86. Dutrillaux et al. reported that near diploid cases 
with less than four rearrangements almost always involved alterations of 1q and/or 16q 
while losses of chromosome segments were more prominent than gains in cases with 
more than four rearrangements85. This is in line with the findings from aCGH analyses of 
diploid tumors; some tumors were of the simplex type, other of the complex 1 or complex 
2 type87. A translocation resulting in a der(1;16)(10p;10p) is identified by karyotypic 
studies and considered an early event in mammary carcinogenesis88, 89. Another early 
event seems to be formation of isochromosome 1q, this gain is also seen in numerous 
studies using array comparative hybridization (aCGH), making 1q gain one of the most 
frequent alterations in breast carcinomas.  
 
Subgrouping breast cancer by ploidy measurements  
The prognostic value of measurements of DNA content in breast carcinomas have been 
debated for decades but it seem evident that breast tumors can be grouped by different 
levels of DNA content90, 91. Breast carcinomas display a wide range of modal values from 
less than 30 to more than 200 chromosomes per cell64. Kronenwett at al. subdivided a 
tumor set into diploid (modal value 1.8c-2.2c), tetraploid (3.8-4.2c) or aneuploid groups 
(one peak or more outside the diploid or tetraploid range)92. By adding a stemline scatter 
index (SSI), each of the three groups was subdivided into being stable or unstable. Their 
study showed that is was of minor importance where the stemline was situated, but the 
scatter indicating an unstable genome reflected a significantly worse prognosis. 
Aneuploid tumors had frequently a hypotetraploid modal value, but a minor group of 
aneuploid tumors were hypodiploid, hyperdiploid, triploid or hypertetraploid. Structural 
chromosomal aberrations and losses of entire chromosomes have been suggested to occur 
first during genetic evolution of breast tumors, and would lead to a transient hypodiploid 
cell clone85. A succeeding doubling of DNA by endoreduplication would result in a DNA 
content ranging from triploid to hypotetraploid tumor depending on the amount of initial 
losses. Alternatively the endoreduplication can occur early and additional rearrangements 
will result in a hypo or hypertetraploid tumor. Hypodiploid tumors have been considered 
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a distinct entity with both clinical and genomic characteristics dominated by losses on 
multiple chromosomes and is associated with a worse outcome93, 94. 
 
Subclasses defined by gene expression patterns 
The intrinsic subtypes 
The gene expression based classification defining five subtypes was the result of the 
works of Perou and Sorlie a decade ago95, 96 in neoadjuvant treated breast carcinomas. 
The expression of approximately 12000 genes was measured by cDNA arrays95. 
Thereafter, genes that had low variation in expression in samples taken before and after 
treatment for each patient and at the same time varied most between all patients were 
extracted. A total of more than 550 genes were thus identified and named the “intrinsic 
gene list” as they were thought to be reflecting the individual tumors phenotype. By 
hierarchical clustering, a pattern of two main clusters with a total of five subclusters 
emerged in several independent cohorts96-100. The largest cluster has frequently two 
groups dominated by ER positive and Luminal cell related genes, one having more 
proliferation related genes upregulated than the other (Luminal A and Luminal B 
respectively). The other main cluster had three groups. One related to myoepitel/basal 
epithelial cell gene expression (such as basal cytokeratins and thus called Basal-like), 
another were dominated by high expression of erbB2 related genes (called erbB2+ group) 
and the third had gene expression not very dissimilar from patterns found in normal 
breast tissue samples (called Normal-like).  
 
The robustness of the subtypes 
By calculated centroids for each of the five main subtypes (Luminal A, Luminal B, 
erbB2+, Basal-like and Normal-like), class prediction can be made for individual 
samples. When making class predictions for the cohort analyzed in paper II, III and IV, 
several of the samples correlated to more than one centroid100. A heat map generated by a 
cluster algorithm illustrates the heterogeneity of the centroid correlation in the sample set 
(Fig. 6).  
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Figure 6: Hierarcical clustering of 123 MicMa samples based on the calculated correlation to the centroid 
for each of the five subgroups. Red indicates positive correlation, green indicates negative (anti-) 
correlation. Dark color indicates correlation close to zero. The rows of the heat map indicate the centroid 
correlation values to Luminal B (1. row), followed by the Basal-like, the erbB2+,the Normal-like and 
Luminal A at the bottom. The clusters reflect the relationship between the different subtypes. .   
 
By using this approach two conclusions can be drawn: 
 
1: There are two main branches, one dominated by samples correlated to the Luminal A 
centroid, the other correlated to the ERBB2+ and/or Basal-like centroid. Samples do not 
have a strong correlation to both the Luminal A centroid and the Basal-like and/or 
erbB2+ centroid. The Basal-like samples have almost always a positive correlation to 
ERBB2+.  
 
2: Samples highly correlated to the Luminal B centroid are found in both main branches, 
some have additional correlation to the Luminal A centroid, others to the Basal-like or 
erbB2+ centroid. Samples highly correlated to the Normal-like centroid are also in both 
main branches, some have additional correlation to the luminal A centroid, others to the 
Basal-like or erbB2+ centroid.  
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An interesting notion is that samples with a high correlation to Normal-like are always 
anti correlated to Luminal B.  
 
From this we can hypothesize that Luminal A and Basal-like are phenotypically diverse 
with regard to intrinsic characteristics.  
 
Surrogate markers for the subtypes 
Immunohistochemical (IHC) staining of tumor sections has revealed that the Luminal A 
tumors are often ER and/or PgR positive while the Basal-like are not. The former have 
several proteins in common with the luminal cell type of the breast (such as ER, PgR, 
CK18, GATA3) while the latter resemble to some extent the myoepithelial cell type, such 
as CK5, 6, 14, 17 and SMA97, 101-103 (for review: 104). Basal-like tumors are often said yto 
be ‘triple negative’ (i.e. negative IHC for ER and PgR and negative IHC/FISH for 
HER2), but is known to be heterogeneous105. Another major difference between Luminal 
A and Basal-like tumors are the frequent finding of single base mutations in genes such 
as TP53 and BRCA1 in Basal-like tumors. Those genes are only rarely mutated in 
Luminal A tumors. Histological patterns of differentiation are linked to the subtypes. 
Carcinomas with lobular and tubular differentiation are almost always of Luminal A type 
while tumors with medullary, adenoid cystic or metaplastic differentiation are of Basal-
like type106, 107.  
Accepting that the phenotype of the tumor is influenced by extra-tumoral factors 
such as tumor microenvironment (stroma, inflammation, endothelium, fat) and 
endogenous and exogenous components such as hormones and other substances, the 
search for genomic alterations for each of the subtypes was important. Several groups 
have found genomic alterations by aCGH that seem to be more frequent in one or more of 
the intrinsic classes56, 57, 108. Bergamaschi showed, in an advance stage cohort, that the 
intrinsic subclasses harbored different genomic alterations108. The Basal-like had higher 
numbers of gains and losses than Luminal A and the Luminal B and erbB2+ had more 
frequent high-level amplifications. Chin and Fridlyand compared their aCGH groups to 
the expression subtypes, and found that Luminal A tumors were dominating the 1q/16q 
group, Luminal A and erbB2+ the mixed amplifier group and Basal-like and Luminal B 
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the complex group56, 57. Another study identified a group of tumors with low genomic 
instability, and found these tumors to be enriched by the Basal-like subtype109. Normal-
like samples are often too few to be studied, and Luminal B can be hard to identify in 
some datasets99. The erbB2+ group was dissolved when the erbB2 amplicon was 
removed from the data in one CGH based study110, but are more distinct as a subgroup in 
others111. 
 
Expression subtypes and epidemiology 
It seems evident that of the molecular expression subclasses, the Luminal A and the 
Basal-like group are regarded as distinct diseases with different genomic changes, 
expression patterns and clinical and histopathological profiles. By using IHC markers 
several epidemiological studies have been perform to identify differences in etiological 
factors101, 112-114. The distribution varies among different ethnical populations with Basal-
like tumors more frequent in African-American than in non African-American women101. 
It is also shown that increasing body mass index reduces the risk of Luminal tumors in 
premenopausal women, and that late menarche reduces the risk of Basal-like 
carcinomas113. Acknowledged risk factors for breast cancer in general seem to only be 
valid for Luminal A tumors; women with fewer children and high age at first full term 
pregnancy had a higher risk of Luminal A carcinomas  than Basal-like114. The increased 
risk of Basal-like carcinomas observed in women with young age at first full time 
pregnancy and in women with high parity and short duration of breast-feeding indicate 
the complementary nature of these two diseases114. Basal-like tumors are also known to 
have an earlier age distribution compared to the Luminal type112.  
 
Breast cancer progression from a molecular point of view 
Several observations of Foulds can now be viewed with the knowledge of molecular 
alterations as seen by multiple different methods investigating different characteristics of 
breast tumors. 
  
 
 
34 
 
Tumors progress independently 
The notion of this came from studies in mice, by having five to six pairs of breast glands 
the probability of having several tumors at the same time is much larger than in humans. 
An interesting aspect is that tumors in the same host can have different paths of 
progression. In a study we performed on bilateral human tumors we saw that the 
distribution of molecular subtypes followed some patterns (paper I). Women with a 
luminal tumor in one breast had almost always a luminal tumor in the other breast. 
Luminal tumors were defined as having either ER or PgR expression, and represent the 
tumor type dependent on the host for instance by hormonal influence (‘responsive 
tumors’). Interestingly, the triple negative tumors in this study had a more heterogeneous 
distribution and are probably of a more ‘unresponsive’ type. 
 
Progression follows alternative paths in luminal and basal related carcinomas 
The findings reviewed above about molecular types of breast carcinomas indicate that 
separate breast cancer tumor types exist and Luminal-A and Basal-like are the most 
acknowledged. 
One type of carcinomas evolves from hyperplasia through low grade pre-invasive 
tumors into invasive carcinoma (IDC/ILC) predominantly of low grade. It also seems 
evident that several tumors do not follow this path but have genome wide rearrangements 
already at the pre-invasive stage. They probably evolve from high grade DCIS into high 
grade invasive carcinomas115. The high grade tumors are frequently ER negative in 
contrast to the low grade tumors dominated by loss of 16q and gain of 1q78, 116, 117. In 
paper II we studied the genomic alterations in 595 tumors aiming at combining the 
knowledge supporting the existence of two main classes of tumors; 1) Luminal A/simplex 
type and 2) the Basal-like/erbB2+/complex type. As seen by others, the alterations 1q 
gain and/or 16q loss recognized a majority of Luminal A tumors (called A tumors) and 
tumors with genome wide alterations were dominated by Basal-like tumors (called B 
tumors).  
The frequent concordance of 1q gain and 16q losses is shown by karyotyping to 
represent centromere close translocations. As shown in Figure 7 multigene interphase 
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FISH identified this translocations in several of the A tumors included in paper II 
(unpublished data).  
 
Figure 7:  
Example of aCGH and FISH analyses from two Luminal A tumors. At the top is the aCGH profile with 1q 
gain and 16q loss in addition to some other alterations. The pictures show two cells from each tumor 
hybridized with five different FISH probes. The illustrations below illustrate the observed combinations of 
the FISH probes compared to the expected combination as it is seen in normal cells indicating a 
der(1;16)(10q;10p) in the tumors. 
 
The abundance of heterochromatin and segmental duplications close to the centromere on 
chromosome 1 might make this a vulnerable area for mitotic over-crossing and 
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subsequent translocation118. Interestingly, chromosome 16 has duplication rich 
centromeric regions with homologous sequences to several chromosomes including chr. 
1, this might also make chromosome 16 vulnerable for such changes 119.  
The data analyzed in paper II suggest that a progression occur in A tumors when 
the tumor genome are able to undergo complex rearrangements. As illustrated in paper II 
the tumors with complex rearrangements (A2 tumors) have overall more alterations than 
those without (A1 tumors) and the clinico-pathological data are in favor of A2 tumors 
representing more advanced progression levels of A tumors. This is in line with Foulds 
hypothesis; tumors can progress by a shift of path. Complex alterations of the firestorm 
type in aCGH profiles are showing high-level gains of regions with intermittent losses. 
Both karyotyping and advanced sequencing of such tumors has revealed that several 
different chromosomes can be involved in complex combinations120, 121. In contrast to 
karyotyping and sequencing, aCGH can only give indications of which arms are involved 
in such complex rearrangements. One mechanism explaining this type of rearrangements 
is the breakage-fusing-bonding principle (BFB cycles), where double strand DNA breaks 
in cells with repair defects can lead to either sister chromatin or non homologous end 
joining followed by a new break during the next mitosis creating amplifications and 
deletions122, 123.  The most frequent arms with complex rearrangements in A tumors were 
8p and 11q. Bautista et al. showed by FISH that alterations on these two chromosome 
arms can be rearranged together in a derivative chromosome, probably due to BFB 
cycles124, although other groups have shown that these events can occur unconnected as 
well125. In MCF7, a well characterized ER positive cell line with complex rearrangements 
on several chromosomes including 17q and 20q, the same phenomenon is seen, resulting 
in functional fusion genes from the two chromosomes121, 126, 127. The results from paired-
end sequencing from one of the A2 tumors reveal the same complex pattern of several 
chromosome arms being intermingled and causing fusion genes (Stephens at al. under 
review, Nature). Recurrent fusion genes rare in breast cancer128, but can be explained in 
wide range of breakpoints from tumor to tumor. High-level amplifications of selected 
regions like 8p11, 11q13, 12p13, 17q12 and/or 20q13 are strong predictors of reduced 
survival 110, 129.  
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Intra-tumor heterogeneity has been acknowledged in breast carcinomas130. One 
study by Navin et al (in press, Genome Research) different parts of tumors were sorted 
into cell fractions with regard to ploidy. This study showed two main types of 
progression; one monogenomic, stable type and one polygenomic more genomic unstable 
type. The latter type had one clone dominated by hypodiploid cells, but also additional 
clones with aneuploid DNA index (triploid area) indicating that a doubling of DNA 
content from a hypodiploid phase has occurred. This is in line with the findings of 
Dutrillaux at al.85. In paper IV the ploidy measurements of Basal-like tumors by ASCAT 
correspond to the distribution seen in the polygenomic group and the measurements for 
Luminal A the distribution of the monogenomic type. Coinciding with the 
aneuploidization of the polygenomic tumors, complex rearrangements occur, in line with 
our findings of B1 tumors being dominated by large regions of losses while the related 
group, B2 tumors, had more gains in addition to complex rearrangements (paper II). This 
switch can explain the close relationship between erbB2+/Luminal B and Basal-like 
tumors; complex rearrangements have frequently amplifications of growth promoting 
genes found, and this can shift the phenotypic pattern more towards the expression 
subtypes such as Luminal B and erbB2+.  As also seen by Chin et al.; if genes whose 
expression was correlating with amplification were removed, the erbB2+ cases did not 
cluster together. This can indicate erbB2+ tumors do not represent a separate path of 
progression but reflects a ‘side-path’ for the main types110. Data from paired-end 
sequencing revealed a very dissimilar rearrangement pattern compared to Luminal A 
tumors. Basal-like tumors had multiple segmental duplications genome wide (paper II). 
The mechanism behind is not known, but in the MicMa cohort we identified two tumors 
of the AB2 and C2 type with this pattern in addition to more complex rearrangements. 
One was Basal-like by expression, the other were erbB2+, again strengthening the 
suspicion of a close relationship between these groups. In addition, this latter case was by 
SNP analyses (paper IV) found to have allelic imbalance of the same type as seen for the 
Basal-like tumors. 
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Progression does not always reach an end-point  
This reflect a phenomenon widely known to be true for some types of prostate 
carcinomas, and when mammography was introduced, it was debated whether the 
increased incidence in the same time reflected tumors that never would have progressed 
to become a clinical detectable tumor during a woman lifetime. Breast tumors are 
estimated to have very different growth rate131. Highly differentiated tumors such as 
tubular carcinomas with only one or two genomic changes (such as 16q loss) might 
represent such tumors83, 131. As mentioned above, no data up to now have been able to 
identify which tumors have the propensity to have secondary changes and develop via 
another path into more aggressive disease.  
 
Epigenetic alterations in breast cancer 
Epigenetic modifications both at the chromatin and DNA level affect the structure and the 
expression of genes and is essential both for normal development but also for regulation 
of tissue specific processes. Several mechanisms are of importance, such as histone 
modification, DNA methylation, non-coding RNA’s and nucleosome position (for 
review; 132, 133. Probably the most widely studied epigenetic modification is the cytosine 
methylation in the context of the dinucleotide CpG. In embryonic stem cells such 
modifications is of major importance in regulating genes important for cell differentiation 
and function134. Altered regulation of CpG methylation is implicated in many diseases. 
Specifically, in cancer, methylation of CpG islands proximal to tumor suppressor genes 
such as p16, Rassf1a, and BRCA1, is a frequent event, and methylation of several gene 
are found to be linked to breast cancer135-138. Knowledge about different methylation 
states characterizing cells at different levels in the breast cell hierarchy is emerging139, 
and in paper III we found a correlation between subgroups of tumors and methylation 
patterns more common in the luminal lineage compared to myoepithelial lineage 
strengthening the relationship between the Luminal A and Basal-like carcinomas with the 
different levels in the hierarchy of normal breast epithelium.  
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Tumor stem cell models 
A key event in carcinogenesis are the acquisition of self renewal capacity46. Self renewal 
capacity is a hallmark of stem cells, and the discovery of subpopulations of cells with 
phenotypic resemblance with stem cells opened for a debate concerning the existence of 
‘cancer stem cells’140. The cancer stem cell theories can be viewed as two different 
models; the cancer stem cell model and  the clonal selection and evolution model (Fig. 
8)15, 141.  
 
Figure 8: The two main models of cancer stem cells; 
A: The cancer stem cell model and B: the clonal selection and evolution model. The dark red cells illustrate 
tumor cells with stem cell capacity, while the brighter cells represent more differentiated progeny causing 
tumor heterogeneity. From Polyak 200715. 
 
Tumor heterogeneity is explained differently in the two models, with programmed 
aberrant differentiation in the first or as a mixture of subclones with difference in the 
latter. The former hypothesis defines the cancer stem cells to be the driver of the 
progression, while the latter defines the clone with the most advantageous aberrations as 
the driver. Both models can explain treatment resistance; either is the stem cell resistant 
or a development of a resistant subclone will explain the progression of the disease. 
Although the models are different, they are not mutually exclusive. It is possible that 
some breast tumor types have a cell of origin with stem cell properties and can develop 
heterogeneous subclones if the ability to differentiate is intact. Others might origin from 
more mature and linage restricted progenitors and subclones with additional alterations 
can explain progression and resistance to treatment. In others and our data the Luminal 
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related tumors fit into clonal selection and evolution model, while Basal-related tumor 
progression can be explained by a stem cell model142, 143. It is of major importance to 
reveal more about the properties and relationship between mammary epithelial cells and 
their predecessors144. 
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Aims of the study 
 
The primary aim of this study was to explore breast carcinomas at the genomic, 
transcriptomic and epigenetic level to identify distinct molecular subgroups of tumors, 
and explore their different progression paths and the clinical impact.  
 
The secondary objectives were: 
 
• to define the relationship between host-related influence and the molecular 
expression subtypes by classifying bilateral synchronous and metachronous breast 
tumors using IHC surrogate markers. 
 
• to elucidate the relationship between genomic alterations, molecular expression 
subtypes, structural rearrangements, ploidy, pathology and clinical data by 
exploring genomic architectural alterations in high-resolution aCGH data from 
different breast cancer cohorts 
 
• To explore genome wide methylation patterns to identify subgroups and their 
relationship to molecular expression subtypes and clinical data.  
 
• To develop bioinformatical tools enabling objective measurements of genomic 
events. 
 
• To develop bioinformatical tools to elucidate the heterogeneity and ploidy in 
tumors in order to adjust genomic copy number values.  
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Material and methods 
 
Patient material 
This study has been analyzing several clinical breast cancer cohorts, but the main focus 
has been on the “MicMa” samples. Four other cohorts were used; one with bilateral 
tumors (“Russian”) and three cohorts with primary tumors (Sweden; “WZ”, Oslo; “Ull” 
and England; “ChinUC”). The details of these cohorts and analyzes performed for each 
study is given in Table 1. Demographic data for all cohorts are given in Paper II 
(Supplementary Table 1).  
As a part of the “micrometastasis” research group at the Norwegian 
Radiumhospital, a study concerning the implication of micrometastasis for breast 
carcinoma patients were launched in 1993 (The DNK study, supported by The Norwegian 
Cancer Association). A total of 921 breast carcinoma patients from five different 
hospitals were enrolled between 1995 and 1998 into the study. Blood, bone marrow, 
tumor tissue and lymph nodes were collected if possible, as well as clinical data including 
10 years follow up145. Fresh-frozen tumor tissue was available from 130 patients, and this 
sub cohort of the DNK study is referred to as the MicMa cohort. The cohort consists 
mainly of primary operable tumors of stage I-III where almost 40% received no adjuvant 
therapy100.  
The ChinUC cohort is selected from a clinical tissue bank to represent low stage 
tumors109. All tumors were primary operable invasive carcinomas collected from 1990-
1996.  
The WZ cohort was highly selected as it was drawn from a tissue bank to study 
diploid tumors with different outcome87. In addition to 100 diploid tumors, 41 aneuploid 
tumors were included.  
The Ull cohort was sequentially collected at a single Norwegian hospital between 
1990-1994 and was dominated by primary operable breast carcinomas of low to 
intermediate stage99.  
 The Russian cohort was collected retrospectively to include equal numbers of 
metachronous and synchronous breast carcinomas.  
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Methods 
 
As noted in Table 1, several different methods were used in this study. An overview of all 
methods is given in Table 2 at the end of this section. By combining data from different 
types of analyzes, we have been able to characterize breast tumor both at the phenotypic 
(Protein, RNA), epigenetic (methylation) and genomic (DNA) level.  
 
Immunohistochemistry 
Immunohistochemistry for protein detection was chosen as it is convenient on FFPE 
tissue and because it allows visually interpretation of which cell type express the chosen 
protein. The method is based on antibodies binding to the chosen antigen (protein) and 
thereafter visualized by different detection systems. The main detection system used in 
this study was Envision+ (DAKO) which has less background and is easier to interpret 
than the previously more common techniques such as the ABC (Avidin-Biotin-
Peroxidase) method 146, 147. The bound antibodies are recognized by a secondary antibody 
coupled to a dextran polymer with enzymes, and after biotin treatment it gives a strongly 
enhanced visual signal as illustrated in Figure 9. Antibody based assays with detection by 
Fluorochromes can also be used as demonstrated in Paper I. 
 
 Figure 9: The principle behind protein detection by polymer based IHC. Modified from Wiedorn et al. 
2001 148. 
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Gene expression microarray analysis 
Measurements of RNA levels of different genes were not a specific part of this study, but 
the classification by expression data are fundamental for all the four papers, so the 
methods will be reviewed briefly. The RNA levels of expressed genes can be made 
individually by quantitative RT-PCR (reverse transcriptase polymerase chain reaction), 
but microarray technology opened for expression analyses of thousands genes at the same 
time. The array type used for expression based classification in paper II and III were 
cDNA arrays consisting of 42 000 cDNA clones selected from expressed a sequence tags 
(EST) library and spotted on glass slides100, 149. Both sample and reference RNA were 
converted into cDNA, labeled by different fluorescent dyes mixed and hybridized to the 
array.  An optical reader measured fluorescent at both wavelengths to be able to calculate 
an intensity ratio (Fig. 10). The ratio reflects genes that are over-, under- or equally 
expressed compared to the reference cDNA.  
The molecular classification 
of breast carcinomas is based on 
previous studies of Sorlie and 
Perou37, 95, 96. Although some 
samples have almost equally high 
correlation to more than one, the 
most common way of classifying is 
to designate each sample to the 
centroid with  
highest correlation as illustrated in 
Figure 11. 
 
 
Figure 10: A schematic illustration of cDNA 
expression array  
hybridization. From Jeffrey et al.149. 
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Figure 11: The gene expression data from the intrinsic gene list is used for hierarchical clustering of the 
MicMa samples (top). The corresponding chart (bottom) illustrates the correlation value to all five 
centroids for each sample. The color of the bars in the cluster diagram show the centroid the given sample 
had the highest correlation to.  From Naume et al.100.  
 
 
Measurement of DNA content  
Measurement of DNA content of the MicMa samples was performed on imprints, made 
by lightly pressing frozen tumor tissue onto glass slides followed by fixation in formalin. 
The staining of DNA was performed by Feulgen reaction; hydrolysis of DNA followed 
by a color reaction (Schiff) as previous described150. The cells were identified visually as 
tumor cells or non-tumor cells (such as lymphocytes and fibroblasts). By image 
cytometry the DNA content was measured in approximately 200 tumor cells and in 
representative non-tumor cells. The optical density of each cell was compared to the 
density of the non-tumor cells and the result from each tumor was viewed in a histogram. 
The histograms in this study was interpreted visually where the mode value of each peak 
were selected as the ploidy value of the tumor. Tumors with mode values between 1.8 
and 2.2 were called diploid while tumors with mode values higher that 2.2 was called 
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aneuploid. Some tumors were purely diploid while others were aneuploid often 
displaying a broad specter of DNA content (Fig. 12).  
 
Figure 12: To the left a histogram from a diploid tumor (top) where almost all measured cells have DNA 
content equally to non-tumor cells (2c). To the right is an aneuploid tumor displaying a broad specter of 
cells with DNA content ranging from below 2c to more than 3c. 
 
Fluorescence In Situ Hybridization; FISH 
To visualize alterations of the DNA structure in more detail, FISH is a technique that can 
both show copy number alterations and structural rearrangements. The HER2 
copynumber was measured by FISH in the MicMa cohort on TMA (tissue micro arrays) 
by commercial probes hybridizing to the gene (Vysis)151. A fluorescent labeled DNA 
probe is designed to be complementary to the target DNA and after hybridization the 
signal will be detected by a fluorescent microscope. DAPI (4’,6-diamino-2-phenylindole) 
are frequently used to visualize the nuclei. Probes can be made in-house both by using 
BAC (bacterial artificial chromosomes) clones and by PCR based techniques. Absence of 
signals can be interpreted as genomic loss, while extra signals indicate gains (Fig. 13). By 
selecting probes close to each other, translocations can be detected either as split signals 
or fused signals. In paper II we designed BAC probes with different fluorescence to DNA 
loci on each side of the centromeres on chromosome 1 and 16 to visualize a translocation 
between the two chromosomes. In paper IV we used probes tailored to frequently 
amplified regions on chr. 8 for validating the copy number estimates made by ASCAT 
(Fig. 14) 
 
Figure 13: FISH analysis revealing copy numbers of  the HER2 gene (red) compared to 
centromere 17 (green) in tumor cells (the nuclei are blue by DAPI). On top is nuclei from 
a tumor with no increase in HER2 copy number, below is a tumor with two copies of the 
centromere 17 and >20 copies of HER2. 
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Figure14: Multigene FISH analyses with five probes targeting different genes on chromosome 8. The 
columns represents photographs taken from each specter, the last column are the superimposed image with 
all signals. The two first rows represent tumor cells, the third row is a lymphocyte serving as an internal 
control.  
 
Copy number microarray  analysis 
Measurement of genomic variations was traditionally performed by karyotyping. Later, 
comparative hybridization with reference DNA on metaphases improved the detection152. 
Almost a decade ago, the first maps of the sequences in the human genome was 
published153. This, together with the technical improvement of array analyses and 
bioinformatical methods, opened for high resolution DNA analyses such as aCGH (array 
comparative genomic hybridization). The first published work with aCGH used a 2400 
BAC array154. The most common type of aCGH is constructed by spotting DNA 
sequences (BAC, PCR fragments or synthetic oligonucleotides based) on glass slides (for 
Review;155). Sample DNA are compared to “standard” DNA (such as DNA from pooled 
blood cells from healthy individuals) marked with different fluorochromes and 
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hybridized to the array.  The arrays are scanned to measure the intensities of the two 
fluorochromes per spot, and the ratio indicate if it is more (gain), less (loss) or no 
difference (no alteration) between the sample DNA and the reference. The amount of 
information from such experiments is enormous and different types of bioinformatical 
algorithms are used for quality control, adjustment of variation and visualization of the 
results.  
As summarized in Table 2, data from three different types of aCGH platforms was 
analyzed in Paper II, and copy number variation deduced from SNP array was used in 
Paper IV. The Roma array (Representational Oligo Microarray Analysis) was developed 
at Cold Spring Harbor Laboratories (CSHL) to identify copy number polymorphisms and 
variations (CNP and CNV)156. In this method DNA was digested by BglII to reduce the 
complexity of the genome but still keep the analysis at a high resolution. The ROMA 
array is spotted with >83 000 DNA fragments distributed throughout the genome as 
illustrated in Figure 15. 
 
Figure 15: The ROMA platform. DNA is cut by BglII prior to adaptor ligation, DNA amplification, 
labeling, mixing with reference DNA and hybridization to the array. From Feuk et al.157. 
 
The Ull cohort was analyzed by an array designed total genomic DNA analyses without 
PCR amplification 158(Agilent). The array is spotted with 244 000 probes with a genome 
wide distribution. The data from the ChinUC cohort was from a custom made 
oligonucleotide based array with approximately 30 000 probes159. All three platforms are 
arrayed with oligonucleotides, but the Agilent and the custom made (ChinUC) are biased 
towards intragenic probes in contrast to the ROMA array. The Illumina SNP array used in 
Paper IV is based on a bead principle160 and measure both signal intensity and changes in 
allelic composition identifying both copy number change and copy number neutral events 
(LOH; loss of heterozygosity)161. Comparison of data obtained from the ROMA, Agilent 
(44K) and Illumina platform has shown only minor discrepancies162.   
50 
 
 
Methylation status analysis 
For study of genome wide methylation we used MOMA (Methylation Detection 
Oligonucleotide Microarray Analysis), also developed at CSHL163. MOMA allows for 
high throughput analysis of classical CpG islands of size 200-2000bp. As for ROMA, 
MOMA is based on representations of DNA. After cutting and ligation with adapters 
each sample is divided into two. One part is digested with McrBC (cleaving DNA at 
methylated cytosine residues), the other part is mock digested to serve as a reference for 
comparative hybridization on the array (Fig. 16).  
 
 
Figure 16: Schematic illustration of the 
principle behind MOMA. Genomic DNA 
is cleaved in CG rich areas, ligated to 
adaptors and split into two. One part is 
digested at methylated cytosine residues, 
the other not. After a balanced PCR 
reaction the two parts are mixed and 
hybridized to the array. From 
Kamalakaran et al.163. 
 
 
 
 
Paired-end sequencing 
In a separate study a minor subset of samples from the MicMa and Ull cohort were 
analyzed by Paired end sequencing (Stephens et al, resubmitted, Nature). In Paper II the 
results from five of the tumors are used to illustrate the differences between the 
subgroups defined by different genomic architecture. In this method, DNA is fragmented 
into 400bp fragments where each end of every fragment are ligated to adapters and then 
sequenced164. The first 37 bases are sequenced from each end of the strands, and then 
mapped to the genome. Ends that do not map as expected indicate a structural 
rearrangement, such as a translocation, duplication, inversion or amplification (Figure 
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17). By mapping several overlapping fragments both breakpoints and type of 
rearrangement can be identified. 
 
 
Figure 17: DNA fragments are sequenced only 
from each end and mapped to the genome. This 
illustrates the identification of a translocation 
between Chromosome 11 and 8, mapped by 
several overlapping fragments. Published with 
permission from P. Stephens. 
 
 
 
Bioinformatical and statistical methods 
Most of the bioinformatical based tools developed in paper II, III and IV are in Java, R or 
MATLAB codes. Statistical analyses were performed by SPSS 15.0 in paper I and II and 
by R in paper III and IV. In paper I and II, associations between categorical or continuous 
values were assessed by Pearson chi square, Fishers exact or Kruskal-Wallis tests165. 
Hierarchical cluster analyses and t-tests used to identify subgroups and altered loci of 
methylation in paper III were performed in R as were the Genetic Algorithm (GA) and 
the survival analyses. The survival analyses in paper II and III were based on the Cox’ 
proportional hazard method and log rank tests165. More detailed description of both the 
bioinformatical codes and statistical methods are given in the respective papers. 
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Summary of results 
 
Paper I: “Paired distribution of molecular subtypes in bilateral breast carcinomas” 
Hege G. Russnes, Ekatherina Sh. Kuligina, Evgeny N. Suspitsin, Ekaterina S. Jordanova, Cees J. 
Cornelisse, Anne-Lise Børresen-Dale, Evgeny N. Imyanitov 
Under review, Molecular Oncology 
 
Tumors arising in both breasts in a female are rare but represent a unique setting 
to explore the relationship between host-related factors and tumor phenotype. In this 
study, we analyzed 100 tumors from fifty women with bilateral disease. Of these, 23 had 
synchronous disease (tumor in the contralateral breast diagnosed within a year from the 
first) and 27 had metachronous disease (tumor in the contralateral breast diagnosed more 
than a year after the first). As the tumors had been preserved as FFPE tissue, we chose to 
classify them into molecular subtypes by IHC. Six antibodies were selected as surrogate 
IHC markers to identify tumors as Luminal (‘Luminal’), triple-negative Basal-like (‘TN-
Basal’), triple-negative unclassified (‘TN-UNC’) or heterogeneously (‘Heterogenous’) 
stained tumors. Clinico-pathological data as well as BRCA1 mutation status were 
available. We found that in bilateral disease, synchronous tumors showed a slightly 
higher rate of concordant pairs than metachronous tumors, and Luminal tumors were 
highly concordant regardless of being synchronous or metachronous. Metachronous cases 
had a higher degree of discordance if the time interval was more than 10 years, and this 
was especially pronounced when the first tumor was of the TN-Basal type. The TN-Basal 
tumors with a short time interval were all concordant, while those with a long time 
interval were highly discordant. These findings points to host related factors being 
important for the development of Luminal-like tumors. The TN-Basal tumors of 
synchronous and metachronous type with short time span were also highly concordant, 
pointing to host related factor in this type of carcinomas as well. In addition, the data 
reflect the acknowledged heterogeneity of Basal-like carcinomas. Metachronous TN-
Basal and TN-UNC tumors with longer time span than five years were highly discordant 
54 
 
and suggest that the second tumor arising in these women have different causes 
dominated by stronger environmental influences than genetic factors. 
This study provides additional evidence for the role of host factors determining 
the molecular subtypes of breast cancer disease, indicating that both germline variations 
and hormonal status are of importance. Such knowledge can provide important 
information about selection of treatment for the first cancer that would also provide as 
prevention for contralateral breast cancer. 
   
 
Paper II: “Genomic architecture characterizes tumor progression paths and fate in breast 
cancer patients” 
Hege G. Russnes, Hans Kristian Moen Vollan, Ole Christian Lingjærde, Alexander 
Krasnitz, Pär Lundin, Bjørn Naume, Therese Sørlie, Elin Borgen, Inga H. Rye, Anita 
Langerød, Suet-Feung Chin, Andrew E. Teschendorff, Philip J. Stephens, Susanne 
Månér, Ellen Schlichting, Lars O. Baumbusch, Rolf Kåresen, Michael P. Stratton, 
Michael Wigler, Carlos Caldas, Anders Zetterberg, James Hicks, Anne-Lise Børresen-
Dale 
Submitted Nature Medicine 
 
The era of genome-wide high resolution analyses have increased the amount of detailed 
knowledge about molecular alterations in breast cancer, but the physical distortion of the 
genome is seldom attributed. In breast carcinomas a variety of structural distortion 
patterns have been identified by karyotyping and this is now supported by detailed 
sequencing analyses. Karyotyping require viable tumor cells and is only appropriate for 
smaller studies, it is time consuming and does not reveal detailed information about 
rearrangements. Sequencing analyzes are costly and time consuming in contrast to aCGH 
analyses. The aim of this study was therefore to construct objective estimates of genomic 
architectural alterations in high-resolution aCGH data and to apply this to several breast 
cancer cohorts to increase sample size in order to be able to explore the relationship 
between genomic alterations, molecular expression subtypes, structural rearrangements, 
pathology and clinical data. By making platform independent scores to 1) identify either 
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gain or loss of whole chromosome arms (WAAI) and 2) identifying complex 
rearrangements of chromosome arms (CAAI), we were able to merge four different breast 
cancer cohorts analyzed on three different aCGH platforms and thus relate genomic 
architectural distortion to various types of data from a total of 595 breast cancer patients.  
By using WAAI, we sub-stratified the merged cohort into Luminal (A tumors) and 
non-luminal tumors (B tumors) based on selected genomic surrogate markers known to 
distinguish the Luminal A and Basal-like subtype. By doing this we also found a group 
with combination of Luminal A and Basal-like markers (AB tumors), and a group with 
none of the markers (C tumors). The selected markers for A tumors were either gain of 1q 
(whole arm) and/or loss of 16q (whole arm), while regional loss on 5q and/or gain of 10p 
were selected as markers for B tumors. The four groups showed that the A group was 
enriched in Luminal A tumors and the B group in Basal-like tumors. Interestingly, 
Luminal B, erbB2 and Normal-like tumors were found in all groups, but the latter two 
subtypes were more frequent in the C tumors. Complex rearrangements as defined by 
CAAI occurred in all subgroups, and were used to subdivide each of them making a total 
of eight different WAAI/CAAI defined groups (A1, B1, AB1, C1 with no/low CAAI and 
A2, B2, AB2, C2 with high CAAI). The groups displayed very different types of genomic 
distortion. The A tumors were dominated by gain or loss of whole chromosomes and 
chromosome arms and B tumors by genomic losses and more regional aberrations. This 
difference were also evident by the few samples selected for paired-end sequencing; the A 
tumor had only one alteration, compared to the B tumor having genome wide duplications 
and several translocations. The complex rearrangements measured by CAAI had distinct 
patterns, with chromosome arms 8p and 11q most frequently affected in A tumors in 
contrast to B tumors having 17q and 20q as frequent affected arms. The pattern of 
genomic distortion and the ploidy status of A and B tumors indicated that a progression 
from A1 to A2 probably occurs along a linear path. Such a progression was less clear for 
the B tumors. A resemblance between B, AB and groups of C tumors probably reflect a 
relationship between the non-Luminal tumors. The WAAI defined groups had significant 
differences in outcome (breast cancer specific death) and CAAI had a strong prognostic 
impact, reflecting that patients with tumors with complex rearrangements, even of only 
one chromosome arm, had a worse outcome independently of other factors. An 
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established prognostic index such as histological grad had a strong prognostic impact in A 
tumors but not in B and AB tumors, reflecting the importance of acknowledging the 
different properties of molecular subgroups. This study show how genomic architecture 
can be used to more robustly define molecular subtypes of breast carcinomas and that 
genomic distortion such as complex rearrangements constitute a new prognostic tool in 
breast cancer. 
 
 
Paper III: “Subtype dependent alterations of the DNA methylation landscape in breast 
cancer and implications for prognosis” 
Sitharthan Kamalakaran, Hege E. Giercksky Russnes, Vinay Varadan, Dan Levy, Jude 
Kendall, Angel Janevski, Michael Riggs, Nilanjana Banerjee, Marit Synnestvedt, Ellen 
Schlichting, Rolf Kåresen, Robert Lucito, Michael Wigler, Nevenka Dimitrova, Bjørn 
Naume, Anne-Lise Børresen-Dale, James B. Hicks 
Manuscript 
 
This study was designed to measure the levels of DNA methylation of breast carcinomas 
by performing high-throughput genome-wide scans of CpG methylation by the MOMA 
technology. By analyzing breast carcinomas (n=114) and normal breast tissue (n=11) we 
aimed at 1) identifying tumor specific methylation patterns, 2) subgroup tumors based on 
methylation patterns and 3) identifying loci with prognostic value. Unsupervised 
hierarchical clustering using the 500 most differentially methylated loci across all tumors 
and the 100 most significant altered loci between tumors and normal tissues clustered the 
tumors into 3 major clusters. As the cohort previously had been classified into the five 
gene expression subtypes, a comparison between the three groups and the molecular 
subtypes was performed. Cluster I, was enriched in luminal subtypes (Luminal A and 
Luminal B) in contrast to cluster II which were dominated by the Basal-like and erbB2+ 
subtypes. Cluster III did not show any expression subtype specific enrichment, the 
majority of the samples belonged to a group of tumors having inconclusive or only weak 
correlations to multiple expression subtypes. The three groups showed a high correlation 
to the DNA based WAAI/CAAI groups as well; cluster I was dominated by A tumors, 
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cluster II by B tumors and cluster III by C and A tumors. Interestingly, the latter cluster 
had only few samples with complex rearrangements. Methylation loci that contributed to 
this clustering were only infrequently localized to CpG islands upstream of genes, 
suggesting that there are subtype dependant genome-wide alterations in the methylation 
landscape in breast cancers. Of the loci mapped to known genes, more than half of them 
showed significant correlation to gene expression, implying possible functional effects of 
the methylation on gene expression. Additionally, distinct expression subtype specific 
patterns of methylation could be detected in known cancer associated genes. CpG islands 
in the HOXA gene cluster and many other homeobox genes were significantly more 
methylated in Luminal A tumors. Several of the loci discriminating between Basal-like 
and Luminal A are known to be differentially methylated in myoepithelial and luminal 
progenitor cells in the normal breast. The methylation patterns of genes characterizing 
Luminal A tumors resemble those identified in CD24+ luminal epithelial cells and the 
loci in Basal-like tumors resemble CD44+ breast progenitor cells indicating that Basal-
like and Luminal A tumors might originate from cells at different levels in the breast 
epithelial cell hierarchy. Furthermore, analysis of these tumors by using follow-up 
survival data allowed an identification of genes whose methylation state was associated 
to poor outcome. 
 
Paper IV: “Novel tool reveals copy number aberrations in tumors (ASCAT)” 
Peter Van Loo, Silje H. Nordgard, Ole Christian Lingjærde, Hege G. Russnes, Inga H. 
Rye, Wei Sun, Victor J. Weigman, Peter Marynen, Anders Zetterberg, Bjørn Naume, 
Charles M. Perou, Anne-Lise Børresen-Dale, Vessela N. Kristensen 
Submitted Nature Biotechnology 
 
In this study, SNP array data from the 102 breast carcinomas were used to deduce tumor 
ploidy, contaminating tissue involvement, intra-tumor heterogeneity and allele specific 
aberrations by a novel bioinformatics approach, ASCAT. SNP arrays measure both signal 
intensity and changes in allelic composition and, in contrast to aCGH, it is possible to 
identify both copy number change and copy number neutral events. ASCAT’s 
consistency and sensitivity to a lowering percentage of aberrant tumor cells was validated 
58 
 
by applying the algorithm to a dilution series of a tumor sample mixed with different 
proportions of its germline DNA. In addition, FISH analyses of selected, frequently 
amplified genomic regions were performed on 11 tumors. The ploidy estimations by 
ASCAT were validated by image DNA cytometry of 79 tumors. The copy number counts 
from FISH analyses were highly concordant with the copy number estimates by ASCAT 
in the selected loci, as were the ploidy estimates compared to the results from image 
DNA cytometry. Together, these validation experiments confirm that ASCAT accurately 
predicts allele-specific copy number profiles of tumors over a broad range of tumor 
ploidy and fraction of aberrant tumor cells. 
Furthermore, ASCAT revealed differences in non-aberrant cell infiltration, ploidy, 
gains, losses, LOH and copy number neutral events between the five molecular breast 
cancer subtypes.  Finally, ASCAT allowed a detection of allelic skewness and by this we 
identified several novel markers of breast cancer.  
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Methodological considerations 
 
All four studies included in this thesis were based upon analyzes of clinical tumor 
samples, either as frozen tumor biopsies or FFPE, in addition were matching blood 
samples used for SNP analyses.  An advantage in usingng clinical samples from different 
patient cohorts is that they a spectrum of the disease including different subtype and 
progression levels can be represented. This is in contrast to functional studies based on 
cell-lines and xenografts, where the diversity of a cohort is lost. The limitations are to be 
acknowledged. It would be unethical to study progression of individual tumors as not 
removing a tumor by surgery would be unethical. Clinical cohorts can have a selection 
bias related to many factors, a bias towards heavily treated patients with large tumors are 
not uncommon. In series such as the Ull cohort sequentially collected by surgeons, 
smaller tumors are often not included as the doctors will not dare to ruin the 
histopathological examination. The MicMa series is part of a larger cohort of patients 
collected at several different hospitals and not only on university hospitals (which can 
have an overrepresentation of large and rarer tumor types). In this cohort 130 tumors had 
fresh frozen tumor tissue available, and these seem to have a skewed distribution towards 
more advanced tumors than the rest of the cohort. Both the WZ and the ChinUC cohort 
was drawn from tissue banks, an advantage is that the tumor samples often are collected 
by a pathologist which can secure also pieces from minor tumors. In the merged cohort 
analyzed in paper II, the WZ tumors (selected for diploids) and the ChinUC tumors were 
important contributors to the descriptive analyses as the set got enrich in tumors probably 
at an early stage of progression. The WZ set was omitted from analyses regarding 
outcome; its selection criteria was to have equal distribution of survivors and non 
survivors. In addition the clinical information was not collected and secured by a 
clinician in contrast to the three other cohorts. 
 Frozen sections were analyzed by microscopy to secure tumor representativity of 
the biopsies, but the variations even in small tumor pieces can be huge. Some tumors 
have huge DCIS components and only minor areas with invasion. An example of tumor 
heterogeneity influencing the analyses was seen in a tumor classified as Basal-like by 
gene expression analyses. The part of the tumor investigated by image DNA cytometry 
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showed a clear diploid profile, while the DNA extracted from another part of the tumor 
showed by ASCAT an aneuploid profile. This is not misinterpretation of the analyses but 
reflect the heterogeneity in some carcinomas.  
 All methods in these four papers have advantages and disadvantages as 
summarized in table 2. The design and properties of each method vary enormously from 
analyzing one target (FISH/IHC) to multiple predefined targets (microarrays) or unknown 
targets (paired-end sequencing). As separate clinical cohorts often have tissue preserved 
differently and of limited amounts, applying the same method on several cohorts is in 
often impossible. In paper I, the state of the tissue made IHC analyses of TMA the 
method of choice to classify the tumors into the molecular subtypes. Selection of markers 
was, as reviewed in the paper, based on previous literature. Due to limitations in tissue 
availability and the work being performed as a collaboration between two laboratories, 
two different detection systems were used. The major problem in classifying this cohort 
was the sample size, and recognizing the major groups was therefore the focus. The 
HER2 marker was of that reason not used as a surrogate marker. It is also debatable if it 
was wise to split the triple negative cases into a ‘TN-Basal’ and a ‘TN-unclassified’, but 
this decision was based on the known heterogeneity of non-Luminal tumors.   
 FISH analyses is to date still difficult to score in an objectively way. A major 
advantage is the in situ visualization of signals in each nucleus. The size, shape and 
location of the signals are important to be able to avoid false interpretations. All counting 
of signals in paper IV was performed visually. To be representative, three to four 
different areas on the imprints were used, and the mean value from 20 cells were chosen 
to represent the copy number for a given gene/probe from each tumor. To identify 
translocations, the same combination of probes needed to be in close approximation to 
each other in several cells to be regarded as a translocation. This is easy to interpret in 
diploid tumors, but much more challenging in aneuploid tumors where the signals were 
more numerous. In such comprehensive FISH analyses using multiple probes it is 
important to keep in mind the few number of cells analyzed, and in heterogeneous tumors 
the findings can probably not be generalized.    
 Ploidy measurements performed by image DNA cytometry and are in this work 
scored visually by choosing the mode value as the DNA index. The histograms from 
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some tumors show broad distributions of DNA content, and a more dynamic type of 
measurements could have been advantageous. In paper II ploidy was used solely as a 
measure for progression and a rough estimate and categorization into diploid and 
aneuploid tumors were therefore used. In paper IV the mode values were compared to the 
ASCAT estimates. Interestingly, most of the tumors that ASCAT could not be applied to 
were highly aneuploid with a broad distribution probably reflecting multiple subclones. 
 Microarray analyses are designed to give information about numerous targets; in 
this thesis the patterns of aberrations have been the main focus and not single genes/loci 
or groups of genes. The use of expression array analyses to deduce the molecular 
subtypes have been discussed previously, but it is important to keep in mind that this 
classification is based on few genes extracted from analyzes on a small tumor set with 
advanced tumors. It is shown that by adding genes to the list, additional expression 
subtypes seem to emerge166. Microarrays measuring copy number variation have various 
types of design, but this thesis point to one major feature; the SNP arrays ability to 
deduce allele specific alterations, measure the influence of non-aberrant cells and deduce 
ploidy state compared to the CGH arrays. The differences between various types of CGH 
arrays can be overcome as illustrated by paper II. Construction of bioinformatical codes 
that easily can be tailored to each type of aCGH data (i.e. centering and PCF 
segmentation) gave data that could be the input to the WAAI and CAAI algorithm 
making these them platform independent. It has to be acknowledged that the probe 
selections on the three types of arrays are fundamentally different, the 32K customized 
array and Agilent being gene centered while ROMA were not.  The WAAI and CAAI 
scores were validated primarily in the ROMA data as HER2 FISH and paired-end 
sequencing was available for several of the tumors. CAAI and WAAI were carefully 
tailored to recognize complex rearrangements and whole arm alterations, and this was 
confirmed by visual inspection of all aCGH profiles. Visual inspection is a subjective 
estimate not good enough as validation, but it was important to do as a quality control of 
the estimates. Samples with whole arm alterations but with either a high standard 
deviation or low amplitude would not get an elevated WAAI score. Such samples are 
difficult to interpret and WAAI was designed to take this into account not to get too many 
false positive scores. This resulted in false negative samples (samples where visual 
62 
 
inspection indicated whole arm gain or loss of 1q and 16q but not classified as A tumors 
by WAAI classification). CAAI was designed to recognize the complex alterations 
defined as regions with high-level amplicons separated by short deletions (firestorms). 
Although the BFB mechanism can in theory explain such alterations, more detailed 
analyses by paired end sequencing indicate that several mechanisms are involved. It is to 
be mentioned that CAAI is not reflecting the complex type of rearrangements called 
‘saw-tooth’, and comparing the WAAI and CAAI distribution in B tumors with the 
frequency plots (Figure 3 and Supplementary Figure 5 in paper II) it is obvious that 
defining a third parameter to capture such rearrangements as well would be an advantage.  
The nature of genomic rearrangements is until now defined primarily by 
cytogenetics, and the transfer of concepts and definitions from karyotyping to detailed 
studies such as paired-end sequencing is difficult. The details about intra- and inter-
chromosomal rearrangements are starting to emerge, and alterations discovered can not 
be fully covered by the existing ‘nomenclature’ of cytogenetics. It is to be expected that 
the new level of resolution in genomic analyses will demand and define such a 
nomenclature, and will bring new insight into the mechanisms behind the different 
architectural distortion patterns we observe in breast carcinomas.   
The studies in this thesis combine information from different analyses in a 
pragmatic way based on established statistical methods. We are in an era where 
integrative approaches are being the main focus in a recently established science called 
‘systems biology’, and major achievements in statistics and bioinformatics are to be 
expected leading to new understanding in the complex field of cancer biology.   
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Main conclusions and future aspects 
 
The studies included in this thesis support the existence of at least two major types of 
breast carcinomas, one with features related to Luminal cells, the other to cells with 
stemcell/Basal-like properties. The tumors progressing along a luminal path are often ER 
and/or PgR positive and can have luminal differentiation as seen by histopathology. This 
phenotype is also reflected by gene expression. At the genomic level such tumors are 
often diploid but have characteristic gains and losses of whole chromosomes or 
chromosome arms, the latter can be explained by whole arm translocation frequently 
involving chromosome 1 or 16. The tumors have a good prognosis, but if luminal tumors 
get more complex rearrangements, the outcome is worse. Such tumors probably reflect a 
more advance stage in progression as they are frequently aneuploid and have high 
proliferation and are less differentiated. An established prognostic factor such as 
histological grade is important to identify patients with a worse prognosis, but this is only 
to be of benefit in luminal related tumors. At the genomic level luminal tumors rarely 
have mutations in TP53, and have few structural genomic rearrangements.  
 The tumors progressing along the Basal-like/stem cell path are typical ER and/or 
PgR negative; expression analyses and methylation patterns link this subtype to basal- 
and stem cells. They have a distinct ploidy pattern being diploid/hypodiploid in a early 
phase and aneuploid close to the triploid region in a later phase. Tumors in the first phase 
are dominated by genomic losses, while tumors in the aneuploid phase are showing 
genome wide complexity including complex rearrangements with high level amplicons. 
Basal-like tumors have minor genomic duplications scattered in the genome, and the 
more advanced tumors seem to have complex rearrangements in addition. This is also 
reflected by the expression pattern as a shift can be observed towards the erbB2+ and 
Luminal B centroid. The mechanism behind this unstable genome is unknown, but 
mutations in TP53 are a frequent alteration.  
 In paper II we found that several tumors could be grouped both as an A and a B 
tumor and were thus designated as AB tumors. By visual inspection they rarely belonged 
to the typical ‘simplex’ (luminal) pattern but had often rearrangements on almost all 
chromosomes, including loss and gain interpreted by WAAI, with whole arm alteration of 
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1q or 16q. Most of the additional analyzes on such samples support that they are related 
to the B/Basal-like type of tumors, but only functional studies can tell if a tumor can 
switch from a luminal path to a Basal-like or vice versa.  
 In addition to these entities minor groups have also emerged; in paper II we 
identify a group of tumors without any of the selected markers which frequently had 
complex rearrangements on 17q. This group was dominated by erbB2+ and normal-like 
samples, and two of the samples were DCIS. As shown in Fig.6 the clustering of the five 
centroid values revealed a group dominated by expression towards the same two 
centroids also indicating an independent type of tumors. 
 To get closer to defining distinct entities and their relationship, the next step will 
be functional studies. As a part of the OSLO2 study, fresh tumor samples are collected 
and disaggregated into single cells preserved in a viable state. Fluorescence Activated 
Cell Sorting (FACS) will be used to sort tumor cells into different fractions by applying 
different antibodies targeting various cell surface markers. The markers will identify cells 
representing different stages in differentiation (such as breast stem cells and more mature 
myoepithelial or luminal related cells) in addition to other cells in breast tissue such as 
fibroblasts, lymphocytes, adipocytes and endothelial cells. Sorted subpopulations will 
further be analyzed both at the genomic level (sequencing/SNP/copy number 
variation/methylation) and at the expression level (RNA/miRNA/protein)  
 If some of the collected tumor samples have viable cells that grow in culture, the 
level of environmental stimuli can be mimicked and varied. The level of differentiation 
can be measured both visually and by gene expression analyzes aiming at identifying 
subgroups of tumor cells that show more or less plasticity with regard to direction of 
differentiation and to investigate whether such changes imply genomic aberrations as 
well.  
 Molecular alterations characterizing a subclone of importance will be selected to 
be analyzed by technologies such as IHC and FISH using tissue sections and TMAs to be 
able to go back to the cohorts used in this thesis where so much additional information is 
available. Such in situ studies will serve as an important validation of findings; it also 
makes it possible to visually identify which cells have the alterations, and where they 
reside in a tissue architectonical context. Larger sample sets of breast carcinoma can thus 
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be analyzed, the clinical impact can be evaluated and the search for a robust molecular 
classification based on more knowledge from the hierarchical relationship can continue. 
If individualized therapy is to become a reality in the near future, a robust molecular 
based classification of breast cancer will be of major importance.   
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Abstract 
 
Distinct molecular subtypes of breast carcinomas have been identified, but translation into 
clinical use has been limited. We have developed two platform independent algorithms to 
explore genomic architectural distortion using aCGH data to measure 1) whole arm gains and 
losses (WAAI) and 2) complex rearrangements (CAAI). By applying CAAI and WAAI to data 
from 595 breast cancer patients we were able to separate the cases into eight subgroups with 
different distribution of genomic distortion. Within each subgroup data from expression 
analyses, sequencing and ploidy indicated that progression occurs along separate paths into 
more complex genotypes. Histological grade had prognostic impact only in the Luminal related 
groups while the complexity identified by CAAI had an overall independent prognostic power. 
This study emphasizes the relationship between structural genomic alterations, molecular 
subtype and clinical behavior, and provides a score of genomic complexity as a new tool for 
prognostication in breast cancer. 
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Breast cancer is a heterogeneous disease as reflected by histopathology, molecular alterations 
and clinical behavior. In order to relate cellular and sub-cellular features to clinical parameters 
and outcome, substantial effort has been exerted towards identifying tumor groups with distinct 
molecular features. Estrogen receptor (ER) status was early shown to be a major discriminating 
factor and is still of clinical importance1. The more recent gene expression based classification 
proposed by Perou et al. in 20002 identified five different subgroups where one was Luminal-
cell related (Luminal A) and another were myoepithelial-cell related group (Basal-like). Three 
additional groups were identified, but these are less characterized (erbB2+, Luminal B and 
Normal-like). Basal-like and Luminal A carcinomas have different etiologies and for most 
purposes may be considered as distinct diseases3-6. This is also reflected in the genomic 
portraits defined by aCGH (array Comparative Genomic Hybridization), and it seems evident 
that the history of molecular subgroups is written in the DNA alterations7-9.  
Despite the power of RNA and DNA based profiling, translating complex molecular 
classifications into clinical practice has proven challenging. Clinical cohorts are often selected 
to have tumors of a certain category, and might not include all subtypes or outcome groups. 
The size of sample sets available for microarray studies has so far been limited, and combining 
sets to increase size has been challenging since various types of array platforms have been 
used. 
Array CGH does not reveal the chromosomal pattern associated with copy number 
alterations; however much can be inferred from cytogenetic studies. The genomic architectural 
changes in breast tumors revealed by karyotyping follow some main traits. One type of events 
seen early in tumor progression is loss or gain of whole chromosome arms10. Another type is 
more complex rearrangements, often involving several different chromosomes with inversions, 
deletions and amplifications10. Previously we found that invasive breast tumors had different 
patterns of aCGH aberrations11. Tumors of the simplex type had few alterations with loss or 
gain of whole arms dominating, while tumors of the complex type had either many 
chromosomes altered with multiple regions with low level loss and gain (sawtooth pattern) or 
had a few selected regions with high copy number gains with intermittent losses (firestorms). 
We hypothesized that distinct molecular mechanisms underlie such patterns of aberrations.  
In this paper, we have developed objective estimates of genome-wide architectural 
distortion. For each chromosome arm, two platform independent scores were defined: one 
measures the deviation from normal copy number (Whole Arm Aberration Index; WAAI) and 
the other the degree of local distortion (Complex Arm Aberration Index; CAAI). The clinical 
impact of WAAI and CAAI was studied using aCGH data from 595 breast carcinomas 
belonging to four clinical cohorts profiled by three different aCGH platforms (30K-244K 
resolution). This revealed patterns of genomic architectural distortion recognizing Luminal and 
Basal related tumors with distinct subgroups and outcome. The study illustrates the importance 
of dividing breast cancer into molecularly defined subgroups as they have independent 
progression paths and clinical outcome.  
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Results 
 
Genomic architecture characterized by CAAI and WAAI 
Two novel algorithms were constructed; one to identify complex architectural distortions 
characterized by physically tight clusters of break points with large changes of amplitude, and 
another to recognize gains and loss of whole chromosome arms (CAAI: Complex Arm 
Aberration Index and WAAI: Whole Arm Aberration Index, respectively). Segmented data 
from one tumor with corresponding CAAI values are illustrated for selected chromosome arms 
in Figure 1a. The circos plot from Paired End Sequencing of the same sample (Fig. 1b) shows 
that CAAI recognizes regions with structural complexity (Stephens et al., resubmitted). Areas 
of complex rearrangements were found by selecting chromosome arms with CAAI  0.5. 
Comparison in one cohort of HER2 copy number gains estimated by FISH and the CAAI score 
showed that all but one sample with high CAAI had more than four copies of HER2 
(Supplementary Fig. 1).  
For most chromosome arms, the distribution of WAAI is approximately symmetric 
around zero (Supplemental Figure 2). For some arms however, WAAI is skewed towards 
positive values (1q, 8q and 16p) and for others towards negative values (16q and 17q), 
reflecting a bias towards gain or loss. This pattern was seen in all cohorts, independent of 
platform. Arms with WAAI  0.8 were defined as whole arm gains and arms with WAAI  -
0.8 as whole arm losses. An example of a tumor with whole arm gain of 1q and whole arm loss 
of 16q is shown in Supplementary Figure 3a. FISH analyses of this case identified a 
combination of probes indicating a centromere-close translocation t(1q;16p) (Supplementary 
Fig. 3b).  
Demographic data for the four cohorts are presented in Supplementary Table 1 and 
overall aberration frequencies are found in Supplementary Fig. 4. The four cohorts were 
merged for the analysis of association to clinico-pathological information, and the frequency 
plot in Figure 2 shows an aberration pattern typical for breast cancer. Several of the most 
frequent events such as gain of 1q and loss of 16q/17q are whole arm events, while the 
majority of gains on 17q and losses on 11q have CAAI  0.5 and are likely caused by complex 
rearrangements (Fig. 2b). A few alterations such as gain on 8q and 20q displayed both whole 
arm gain and high CAAI. 
 
Defining subgroups based on genomic architecture 
Several studies have shown that the number of genomic alterations and the regions 
preferentially altered differ between the molecular expression subtypes7, 8, 12, 13. Luminal A/ER 
positive tumors often have few alterations with gain of 1q and loss of 16q dominating7, 8, 12-14 
while Basal-like have many alterations affecting most of the chromosomes. Loss on 5q and 
gain on 10p have been proposed as specific Basal-like alterations7, 8, 12, 15, similar to findings in 
breast carcinomas from BRCA1 carriers16, 17. Based on this, we distinguish between four 
“WAAI groups” of tumors: those with whole arm gain of 1q and/or loss of 16q (group A), 
those with regional loss on 5q and/or gain on 10p (group B), those with both (group AB), and 
those with neither (group C) (see M&M). To further characterize these groups we split each 
into two “CAAI subgroups” depending on the level of complex rearrangement: those with 
CAAI < 0.5 for all arms (A1, B1, AB1, C1) and those with CAAI  0.5 for at least one arm (A2, 
B2, AB2, C2). The group distribution was similar for all four cohorts, except for the WZ which 
had more samples of type C and less samples with elevated CAAI, most likely due to selection 
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of diploid tumors (Supplementary Table 2)11. The sample size of the eight groups and the arm-
wise distribution of WAAI and CAAI for all 595 samples are shown in Figure 3a. 
 
Patterns of genomic architecture in the WAAI/CAAI groups 
WAAI and CAAI characteristics 
WAAI and CAAI revealed different chromosomal event distributions in the eight subgroups 
(Fig. 3a). This is also reflected in the frequency plots of individual subgroups (Supplementary 
Fig. 5). The subgroups displayed pronounced differences with respect to the number of whole 
chromosome arm loss or gain events (Fig. 3a and Supplementary Fig. 6). For each of the four 
WAAI groups, the tumors with complex rearrangements (i.e. A2, B2, AB2 and C2) had more 
whole arms affected, mostly by gains (WAAI  0.8), than the corresponding group without 
complex rearrangements. 
Tumors of type A were frequently ER positive, of low or intermediate grade, diploid 
and included a majority of the invasive lobular carcinomas (Supplementary Table 3). Group A 
was the only group with frequent alterations of whole chromosomes; particularly prominent 
were gain of 5, 7, 8 and 20 and loss of 18 (Fig. 3a), in line with previous cytogenetic findings18, 
19
. Supplementary Fig. 7 illustrates that A1 and A2 tumors had the same distributions of altered 
arms, and the increased number of gains seen in A2 tumors were mainly affecting 8q, 16p, 20p 
and 20q. In tumors of type A2, complex rearrangements were most frequent on 11q and 8p, 
followed by 17q and 8q (Supplementary Fig. 8). The high level amplifications on 8p and 11q 
includes genes of interest such as FGFR1 and CCND1, loci known to be frequently amplified 
in ER positive breast carcinomas20-22.  
Tumors of type B were more frequently of high grade, aneuploid and TP53 mutated 
than tumors of type A (Supplementary Table 3). Tumors of type B1 were dominated by whole 
arm losses, most frequently of 17p, 4p, 4q and 5q, while tumors of type B2 had complex 
alterations often affecting many arms, most frequently 17q, followed by 8p and 20q (Fig. 3a 
and Supplementary Figs. 6, 7 and 8). The overall frequencies of aberrations were quite similar 
in B1 and B2 (Supplementary Fig. 5).  
AB tumors had elements of both A and B tumors, were dominated by aneuploid tumors 
of intermediate or high grade, and had the highest frequency of whole arm alterations (both 
gains and losses) (Supplementary Table 3, Supplementary Fig. 6 and 7). The AB tumors with 
complex rearrangements had a heterogeneous distribution pattern of arms with high CAAI 
(Fig. 3a, Supplementary Fig. 8).  
C tumors had the fewest numbers of whole arm alterations with 8q and 16p gain and 
17p and 22 loss as the most frequent (Fig. 3a and Supplementary Fig. 6 and 7). This was seen 
both in C1 and C2 carcinomas, with 17p being more frequently lost in C2 than in C1. High 
CAAI was frequent on 17q but rare on 11q (Fig. 3a and Supplementary Fig. 8). The clinico-
pathological parameters had similarities with the A group, but with fewer ER positive and 
more TP53 mutated tumors (Supplementary Table 3). Interestingly almost half of all tumors 
with histological grade 1 and most carcinomas of a special histological type such as lobular, 
tubulolobular and mucinous were grouped as C1.  
 
Paired-end sequencing 
Paired-end sequencing was performed on a few selected samples (Stephens et al., resubmitted 
and Fig. 3b). The analyzed A1 tumor showed a single rearrangement, in contrast to the A2 
tumor which had a larger number of complex inter- and intra-chromosomal rearrangements, in 
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line with the high CAAI score. The 1q/16q translocation in the A1 tumor is missed as the 
paired-end sequencing method does not detect alterations involving centromere-close 
heterochromatin. The B1 tumor showed numerous smaller structural rearrangements (“mutator 
phenotype”) in contrast to the pattern seen in the A1 and A2 tumors. The AB2 tumor showed a 
mutator phenotype pattern, but with more inter-chromosomal rearrangements than the B1 
tumor. The C2 tumor had some segmental duplications/inversions in addition to complex 
rearrangements involving chromosome arm 17q.  
 
Gene expression classification 
For the 298 tumors with available gene expression data, the correlation to the five intrinsic 
subtype centroids was calculated5. Both A1 and A2 tumors showed strong correlation to the 
Luminal A subtype (Fig. 3c). Luminal B tumors were more frequent in the A2 group, 
indicating that A2 tumors represent more advanced tumors with high proliferation and 
increased growth factor signaling than A123 (Supplementary Table 4). This was also supported 
by ploidy data as the A2 group had a higher fraction of aneuploid tumors (Supplementary Fig. 
9). The B1 tumors were dominated by the Basal-like subtype. The subtype correlation patterns 
of B2 and AB1/AB2 were quite similar, dominated by negative correlation to the Luminal A 
subtype, and overall had a closer resemblance to B1 than to A1/A2. A majority of erbB2+ and 
Normal-like tumors were classified as C tumors. Normal-like tumors are rare and often omitted 
from breast cancer expression classification studies, but Normal-like cell lines have shown an 
enrichment in stem-cell related features24. Almost 30% of all Basal-like tumors were classified 
as C tumors, in line with a previous study identifying a subgroup of Basal-like having low 
genomic instability13.  
 
WAAI and CAAI groups as prognostic markers 
DCIS patients and the WZ cohort were omitted from survival and risk analyses to avoid bias as 
they were highly selected, leaving 451 cases. Both WAAI and CAAI classification identified 
subgroups with significant difference in breast cancer related death (p=0.009 and p<0.001 
respectively; see Fig. 4a and b). Bivariate Cox regression analysis showed that CAAI 
classification had predictive power independently of age, lymph node status, tumor size, 
histological grade, ER status, TP53 mutation status, vascular invasion, intrinsic subtype and 
adjuvant treatment (Supplementary File 1). Furthermore, the increased risk of breast cancer 
specific death in patients with high CAAI was independent of known risk factors (multivariate 
Cox analysis; HR:1.92, 95% CI [1.33-2.78], p<0.001) (Table 1a). 
For the WAAI classification, patients with B tumors had an almost twofold risk of 
death from breast cancer compared to patients with A tumors (Supplementary File 1). Bivariate 
Cox analysis showed that this was independent of age, tumor size, lymph node status, vascular 
invasion and adjuvant treatment (Supplementary File 1). High histological grade, large tumor 
size and positive node status indicated increased risk for breast cancer specific death for 
patients with A tumors, as opposed to B tumor patients (Supplementary File 1). Interestingly, 
histological grade was non-informative for patients with B and AB tumors but of high 
importance for patients belonging to the A and C groups (p=0.58, p=0.68, p=0.02 and p=0.03; 
Figure 4e-h). TP53 mutation status and high CAAI were the only factors having prognostic 
value (though borderline) in patients with B tumors, while histological grade, tumor size, 
lymph node status all were of importance in the C group patients (Supplementary File 1).  
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The classification obtained by combining WAAI and CAAI also revealed distinct 
patterns of clinical behavior; the worst clinical outcome was seen in the B2/AB2 groups with a 
2.6 fold increase in breast cancer death risk compared to the groups without high CAAI 
(p<0.001) (Fig. 4c and Table 1b). The same trend in survival was seen for patients with lymph 
node negative disease (Fig. 4d).  
 
 
Discussion 
Genome-wide, high resolution analyses of both DNA and RNA have brought novel insights 
into breast carcinoma classification8, 13, 25, but conclusions have been limited by small samples 
sizes. By developing platform independent algorithms, we could merge aCGH data from 
several clinical cohorts and perform DNA based grouping of breast carcinomas, utilizing 
previous DNA and RNA classifications.  Defining surrogate markers for Luminal and Basal-
like breast cancer, we observed several distinct patterns of aberrant genomic architecture. 
Tumors of type A are dominated by ER positive, Luminal A tumors with large WAAI 
magnitude (both gains and losses), and by concomitant 1q gain and 16q loss caused by 
unbalanced centromere-close translocations between the two chromosomes26. The same 
mechanism affecting other arms might explain the frequent losses and gains of whole 
chromosome arms in group A. Several studies have indicated that Luminal tumors have a 
distinct progression path27-30. This is reflected in our study by A2 tumors having more arms 
with high WAAI magnitude, being more frequently aneuploid, of high grade and with worse 
outcome than A1 tumors (Fig. 3a). Amplification is found to precede aneuploidization in breast 
cancer cell lines31, and our study indicates that the same switch also occurs in vivo. Progression 
from A1 to A2 seems to induce a shift in gene expression pattern with increased correlation to 
the Luminal B centroid and worse outcome (Figs. 3c and 4c). 
The B tumors had a completely different and more heterogeneous genomic pattern. Group B1 
tumors were dominated by losses, and the single B1 case investigated by paired-end 
sequencing had in addition the typical mutator phenotype pattern reflecting multiple segmental 
duplications. In two separate studies we have found that a subgroup of Basal-like tumors are 
characterized by losses and progress from hypodiploid to aneuploid, often with complex 
rearrangements (Navin N. et al., in press Genome Research, van Loo P. et al., submitted), in 
line with the B1 group being dominated by losses. Both AB and some C tumors had an 
expression pattern pointing towards a Basal-like relationship (Fig. 3c), In addition, both AB2 
and some C2 tumors had the highest genomic distortion, were often aneuploid and had short 
survival, and we hypothesize that B2, AB2 and some C2 cases reflect more advanced Basal 
related tumors. Interestingly, the ER status cannot be used as a surrogate marker for these 
groups as a large number is ER positive.  
We find that A and B tumors are different both at the genomic, transcriptomic and 
clinical level. It has been shown that amplifications on 8p/11q and 8q/17q occurs preferentially 
in two phenotypically diverse groups of breast cancer32, consistent with the different CAAI 
distribution in A and B tumors. In a study using high resolution methylation arrays on one of 
the cohorts, we found patterns of methylation in A tumors pointing towards CD24+/luminal 
cell relationship and likewise a connection between B tumors and CD44+/progenitor cell 
methylation patterns (Kamalakaran et al., manuscript). There are several indicators that 
molecular subgroups of breast cancer reflect transformation of different breast epithelial cell 
progenitors33-35. Our study indicates that molecular subgroups can be recognized by differences 
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in genomic architecture. This is probably reflecting underlying subgroup-specific defects 
linked to different cell of origin. As illustrated in Figure 5, we hypothesize that the genomic 
architectural pattern reflects tumor subgroups related to different cell of origin. Tumors of type 
A originate from Luminal-committed progenitors and are prone to whole arm translocations. 
They have a linear progression path with complex rearrangements with more arms affected. 
Tumors of type B, AB and C have a much more complex progression path, possibly originating 
from less differentiated progenitors.  Basal-like carcinomas are composed of several 
subtypes36-38, and recent work indicates that a Luminal progenitor on a background of BRCA1 
deficiency may be the cell of origin of such Basal-like tumors39. We suggest that the 
heterogeneity seen in groups B, AB and C with respect to the distribution of WAAI and CAAI, 
indicates that tumors of these types descend from different but related early progenitors, and 
that alternative combination of repair defects defines several progression paths as illustrated in 
Figure 5.  
Complex rearrangements as defined by CAAI occurred in all subgroups, and CAAI had 
a strong prognostic impact independent of other factors, even if it only occurred on one 
chromosome arm. The mechanisms behind complex rearrangements are not completely 
understood, but one type is breakage-fusion-bridge cycles due to double strand repair defects40, 
41
 resulting in high level amplicons with intermittent deletions. As high level amplicons are 
seen even in DCIS42 and in diploid tumors11, this opens the possibility for a distinct subtype of 
carcinomas having complex alterations at an early stage of progression (“de novo 
complexity”). As illustrated in Figure 5, we speculate that the C group might have a subset of 
tumors with a non-A, non-B relationship.  
The present study indicates that the type of architectural distortion is of major 
importance in determining the tumor phenotype and can be used to group tumors into Luminal 
and Basal-related tumors. This is of major importance, since the value of established 
prognostic markers is subgroup dependent. We also find that even in biological distinct 
subtypes of breast cancer, the addition of complex rearrangements seem to be of major 
importance for patient outcome. A strong hierarchical relationship between subtypes of breast 
carcinomas is yet to be defined, but our findings provide a background for further functional 
studies aiming to elucidate the relationship between genomic architecture, phenotypic traits 
and the cell of origin in breast cancer. Our study demonstrates that the patterns of genomic 
architecture described here constitute a new prognostic tool in breast cancer. 
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Figure legends 
 
Figure 1: CAAI pattern compared to structural rearrangements identified by paired-end 
sequencing  
a: Raw (dots) and segmented (line) data for chromosome arms 7p and 8p and chr.15 from 
sample 595. Red segments correspond to the 20 Mb window with highest CAAI; the 
corresponding CAAI was 7.04, 1.04 and 4.74 respectively. Chromosome arms 7p had an 
additional region with elevated CAAI, but as this score was lower than 7.04 it was neglected. 
b: Structural sequence alterations identified by genome wide paired-end sequencing for the 
same sample. Outer circle show the cytobands for each chromosome, followed by a plot 
indicating the copy number variation. The green bars in the centre refer to smaller intra-
chromosomal changes such as duplications and inversions while pink lines indicate inter-
chromosomal translocations. In this sample 13 chromosome arms had CAAI>0, six of these 
had CAAI0.5, these are in bold and marked with *. The two regions with most 
rearrangements showed the highest CAAI (chromosome arm 7p and chr.15). Areas with few 
rearrangements had low or zero CAAI. 
 
Figure 2: Genome wide distribution of genomic loss and gain compared to frequencies of 
WAAI and CAAI in 595 breast carcinomas 
a: Frequency plot illustrating  the percentage of samples with gain and loss genome wide (red: 
gain, green: loss).   
b: The frequency of samples scored with whole arm changes identified by WAAI and complex 
rearrangements scored by CAAI are shown in the heatmap. The color indicates the percentage 
arms with WAAI over and under the chosen threshold and the percentage of arms with CAAI 
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higher than the threshold for each chromosome arm with: WAAI0.8 (red, top row), WAAI-
0.8 (green, middle row) and CAAI0.5 (blue, bottom row). 
          
Figure 3: Genome wide distribution of WAAI and CAAI for all samples sorted into 
WAAI and CAAI groups, examples of identified structural aberrations and 
corresponding gene expression patterns. 
a: The heat map illustrate the WAAI and CAAI score for all 595 samples sorted into A, B, AB 
and C tumors and thereafter into groups of tumors with and without high CAAI on one 
chromosome arm or more. Each row in the heatmap corresponds to one sample, and each 
column to a chromosome arm (from 1p to 22). The left panel indicate WAAI alterations for 
each chromosome arm (red: WAAI0.8, green; WAAI-0.8, black: 0.8>WAAI<-0.8). The 
right panel indicate the corresponding CAAI score for each chromosome arm for the same 
samples (no rearrangements=white. The CAAI scale is indicated below the figure).  
b: Structural sequence alterations identified by genome wide paired-end sequencing for 
selected samples from the various WAAI groups. Outer circle show the cytobands for each 
chromosome, followed by the copy number variation. The green bars in the center indicate 
smaller intra chromosomal changes while pink lines indicate inter chromosomal translocations. 
The lines indicate the position of the selected samples in the WAAI/CAAI groups. 
c: Correlation to each of the five intrinsic subtypes for a total of 185 cases sorted into 
WAAI/CAAI groups.  
 
Figure 4: WAAI and CAAI groups and breast cancer specific survival in the merged 
clinical dataset (n=454 cases) 
The Kaplan Meier plots illustrate that breast cancer patients with tumors with high or low 
CAAI (a) had significant difference in survival (p<0.001). A difference was also found 
between patients with A, B, AB and C tumors (the WAAI groups) (b) and between patients 
subdivided into the combined WAAI/CAAI groups (c). The Kaplan Meier curves showed that 
B2 and AB2 had the worst survival; in a multivariate Cox regression model these patients had 
an increased hazard of 2.6 of dying from breast cancer compared to the A1, B1, AB1 and C1 
patients with a 95% CI: [1.66-4.16] and p<0.001 (Table 1b). 
Patients with lymph node negative disease (n=231) showed the same trend in survival for the 
different WAAI/CAAI subclasses, with B2 and AB2 having a worse prognosis and the A2 and 
C2 having better compared to the whole cohort (p=0.057).   
In e-f, the different impact of histological grade is illustrated. Patients with an A or C tumor 
were stratified into good, intermediate and bad prognosis by histological grade (p=0.02 and 
p=0.03) in contrast to patients with B and AB tumors where we could not show any difference 
in breast cancer specific survival according to histological grade.  
 
Figure 5: A hypothetical relationship between observed patterns of genomic architecture, 
expression subtype and cell of origin in breast carcinomas 
We hypothesize here that a luminal developmental pathway originates from a dedicated 
luminal progenitor cell.  Tumors of the A1 type have ‘simplex’ aCGH profiles with whole 
chromosome or chromosome arm rearrangements dominating. In an early phase a Normal-like 
or Luminal A expression pattern dominates. This in contrast to A2 tumors that are more 
advanced with increased numbers of chromosome arms affected in addition to complex 
rearrangements in preferential regions such as 8p and 11q. These tumors have frequent 
 11
expression correlation to Luminal B in addition to Luminal A but rarely to the erbB2+ 
centroid. The simplicity of A1 tumors are illustrated by the circos plot with only one structural 
rearrangement and the histology illustrating the frequent finding of high luminal differentiation 
in this group. In the A2 group the circos plot show more inter- and intra chromosomal 
rearrangements, and the histology show the more frequent low differentiation pattern.  
Likewise we observe that B1 tumors are different from A1/A2 tumors and hypothesize that they 
originate from a less dedicated or a myoepithelial progenitor. They are dominated by ‘sawtooth 
pattern’ and genomic losses in an early phase and with a high correlation to the Basal-like 
expression subtype. Related groups are B2, AB2 and C2 representing tumors with numerous 
aberrations genome wide including complex rearrangements such as firestorms. This is 
supported by the circos plots from a B1, AB2 and C2 tumor, all having segmental duplications 
genome wide. The histology rarely showed any luminal differentiation and had a solid growth 
pattern with and without lymphoid infiltration. These tumors have correlation towards the 
erbB2+ and Luminal B expression centroids in addition to the Basal-like. The B1, B2, AB2 and 
C2 tumors might represent different stages in a non-linear progression. We also speculate that a 
subgroup of C2 represent tumors with complexity present already in an early phase (‘de novo 
complexity’).  
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Table 1: Multivariate Cox regression analysis, breast cancer specific death 
a)     
 Multivariate Cox regression 
Variable p value HR 95% CI 
n=398     Lower Upper 
     
CAAI (high vs. low) 0.001 1.92 1.31 2.81 
     
Lymph node status (pos. vs. 
neg.) 0.002 1.81 1.24 2.63 
     
Tumor size      
pT2 (vs. pT1) 0.055 1.47 0.99 2.17 
pT3 and pT4 (vs. pT1) <0.001 3.08 1.70 5.60 
     
Histological grade     
Grade 2 (vs. Grade 1) 0.100 1.95 0.88 4.34 
Grade 3 (vs. Grade 1) 0.007 2.98 1.34 6.63 
          
ER status and WAAI classes were also in the model but did not reach  
statistical significance.      
     
b)     
 Multivariate Cox regression 
Variable p value HR 95% CI 
n=398     Lower Upper 
     
aCGH/CAAI grouped into three:     
A2, C2 (vs. A1, B1, AB1, C1) 0.033 1.59 1.04 2.44 
B2, AB2 (vs. A1, B1, AB1, C1) <0.001 2.63 1.66 4.16 
     
Lymph node status (pos. vs. 
neg.) 0.003 1.79 1.23 2.61 
     
Tumor size     
pT2 (vs. pT1) 0.122 1.37 0.92 2.04 
pT3 and pT4 (vs. pT1) <0.001 3.02 1.66 5.48 
     
Histological grade     
Grade 2 (vs. Grade 1) 0.105 1.94 0.87 4.31 
Grade 3 (vs. Grade 1) 0.010 2.88 1.29 6.43 
          
ER status was also in the model but did not reach statistical significance.  
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Methods 
 
Patient samples and gene expression data 
Two cohorts from Norway (MicMa and Ull), one from Sweden (WZ) and one from England 
(ChinUC) were included in this study and the clinical and pathological descriptions are 
available in Supplemental Table 1. Gene expression data, ploidy, sequencing and clinical data 
are previously published 13, 43, 44(ploidy: van Loo P. et al., submitted, sequencing: Stephens et 
al., resubmitted). 
The ethical boards of all institutions involved for the different cohorts have approved the study. 
 
aCGH platforms and preprocessing of raw copy number data 
DNA from the MicMa cohort were hybridized to the ROMA (Representational Oligonucleotide 
Microarray Analysis) 85k microarray, developed at Cold Spring Harbor Laboratory45. The method is 
based on oligonucleotide probes designed after the restriction fragments from digestion with Bgl II. The 
platform is manufactured by NimbleGen, and the experiments followed the ROMA/NimbleGen protocol 
as previously described11. Probe intensities were read with the GenePix Pro 4.0 software and used for 
ratio calculation. The data from both the MicMa and WZ cohort were normalized using an intensity-
based lowess curve fitting algorithm. The aCGH data from WZ is also published11 and accessible from 
http://roma.cshl.edu. 
DNA from the Ull samples was analyzed using 244k CGH microarrays (Hu-244A, Agilent 
technologies, Santa Clara, California, USA). This platform contains over 236.000 mapped in-situ 
synthesized oligonucleotide probes representing coding and non-coding sequences of the genome46. The 
standard Agilent protocol was used, without pre-labeling amplification of input genomic DNA. Scanned 
microarray images were read and analyzed with Feature Extraction v9.5 (Agilent Technologies), using 
protocols (CGH-v4_95_Feb07 and CGH-v4 91 2) for aCGH-preprocessing which included linear 
normalization.  
DNA from the Caldas cohort were as previously described13 analyzed with a customized 
oligonucleotide microarray containing 30k 60-mer oligonucleotide probes representing 27800 mapped 
sequences of the human genome47. Signal intensities and fluorescent ratios were obtained with BlueFuse 
version 3.2 (Bluegnome). Raw data were preprocessed using the R48 with the bioconductor package 
limma49. 
The raw data and preprocessed data can be accessed from NCBI’s GEO 
(http://www/ncbi.nlm.nih.gov/geo/ ) with accession number GSE8757 (ChinUC), GSE…. 
(Ull), GSE…. (MicMa) and GSE…. (WZ). 
 
Statistical methods and analytical tools 
Segmentation into regions of constant copy number 
We fit for each sample a piecewise constant regression function to the log-transformed aCGH 
data, using the PCF algorithm (9,43). For each probe a fitted value (“PCF-value”) is thus 
obtained. The user controls the sensitivity of the method (via a “penalty parameter” gamma) 
and the least allowed number of probes in a segment (kmin).  In our case, segmentation was to 
be performed on data from three different platforms with relative probe densities (average 
number of probes per unit distance) 0.12 (ChinUC), 0.34 (MicMa/WZ) and 1.00 (244k Ull). As 
we aimed to pool all the segmented aCGH profiles, we scaled the parameters gamma and kmin 
to obtain roughly equal segmentation resolutions in the three platforms (thus essentially 
favoring variance reduction over bias reduction in the estimated copy number profiles for 
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increasing probe densities). The chosen values for (gamma,kmin) were (100, 20) for Ull,  (34, 
7) for MicMa/WZ and (12, 3) for ChinUC and are consistent with this. 
 
Centering of copy number estimates 
To center the segmented data, we find the density of the PCF-values using a kernel smoother 
with an Epanechnikov kernel and a window size of 0.03.  Consider the three tallest peaks P1 , 
P2 , P3  in the density, in decreasing order of height (if there are less than three peaks, we 
replicate the highest one to obtain three peaks). For each, we find the location and relative 
height (i.e. the absolute height of the peak divided by the sum of the heights of the three 
highest peaks).  Select among P1, P2 the peak P with location closest to the median of the PCF-
values.  If the relative height of P is at least 0.2, then the PCF-values are centered by 
subtracting the location of P; otherwise, the PCF-values are centered by subtracting the 
location of the tallest of all the three peaks.    
  
Whole Arm Aberration Index (WAAI) 
WAAI is found separately for each arm and sample. Define normalized PCF (NPCF) values as 
centered PCF-values divided by the residual standard deviation. Average NPCF over all probes 
on the arm to obtain s.  If s>0, WAAI is the 5% quantile of NPCF; if s0, WAAI is the 95% 
quantile of NPCF (in practice constrained to a predefined grid). Arms with WAAI0.8 are 
called as whole-arm gains, and arms with WAAI-0.8 are called as whole arm losses. See 
Supplemental Figure 3 for an example.  
 
Complex Armwise Aberration Index (CAAI) 
CAAI is found separately for each arm and sample. For each break point found by PCF, we 
calculate three scores P, Q and W reflecting the proximity to neighboring break points, the 
magnitude of change and a weight of importance: 
 
where  is a constant,  L1, L2 are the number of probes and H1, H2 the PCF-values for the 
segments joined at the break point.  For any genomic subregion R we may define 
 
, 
 
summing over all break points in R. Define CAAI as the maximal value of SR across all 
subregions R of a predefined size (in this paper: 20 Mb). 
 
The software used in this paper is partially written in Java and partially in Matlab, and is 
available at http://www.ifi.uio.no/bioinf/Projects/GenomeArchitecture. For statistical analysis 
SPSS 15.0 was used. The clinical data and WAAI and CAAI estimates are available in 
Supplementary File 2.  
 
 
 
 15
Reference List 
 
 1.       Effects of chemotherapy and hormonal therapy for early breast cancer on 
recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 
1687-1717 (2005). 
 2.      Perou,C.M. et al. Molecular portraits of human breast tumours. Nature 406, 
747-752 (2000). 
 3.      Carey,L.A. et al. Race, breast cancer subtypes, and survival in the Carolina 
Breast Cancer Study. JAMA 295, 2492-2502 (2006). 
 4.      Millikan,R.C. et al. Epidemiology of basal-like breast cancer. Breast Cancer 
Res. Treat. 109, 123-139 (2008). 
 5.      Sorlie,T. et al. Repeated observation of breast tumor subtypes in independent 
gene expression data sets. Proc. Natl. Acad. Sci. U. S. A 100, 8418-8423 (2003). 
 6.      Dalgin,G.S. et al. Portraits of breast cancer progression. BMC. Bioinformatics. 
8, 291 (2007). 
 7.      Bergamaschi,A. et al. Distinct patterns of DNA copy number alteration are 
associated with different clinicopathological features and gene-expression subtypes of 
breast cancer. Genes Chromosomes. Cancer 45, 1033-1040 (2006). 
 8.      Chin,K. et al. Genomic and transcriptional aberrations linked to breast cancer 
pathophysiologies. Cancer Cell 10, 529-541 (2006). 
 9.      Chin,S.F. et al. Using array-comparative genomic hybridization to define 
molecular portraits of primary breast cancers. Oncogene(2006). 
 10.      Dutrillaux,B., Gerbault-Seureau,M., & Zafrani,B. Characterization of 
chromosomal anomalies in human breast cancer. A comparison of 30 paradiploid 
cases with few chromosome changes. Cancer Genet. Cytogenet. 49, 203-217 (1990). 
 11.      Hicks,J. et al. Novel patterns of genome rearrangement and their association 
with survival in breast cancer. Genome Res. 16, 1465-1479 (2006). 
 12.      Adelaide,J. et al. Integrated profiling of basal and luminal breast cancers. 
Cancer Res. 67, 11565-11575 (2007). 
 13.      Chin,S.F. et al. High-resolution aCGH and expression profiling identifies a 
novel genomic subtype of ER negative breast cancer. Genome Biol. 8, R215 (2007). 
 14.      Farabegoli,F. et al. Simultaneous chromosome 1q gain and 16q loss is 
associated with steroid receptor presence and low proliferation in breast carcinoma. 
Mod. Pathol. 17, 449-455 (2004). 
 16
 15.      Vincent-Salomon,A. et al. Identification of typical medullary breast carcinoma 
as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular 
entity. Breast Cancer Res. 9, R24 (2007). 
 16.      Johannsdottir,H.K. et al. Chromosome 5 imbalance mapping in breast tumors 
from BRCA1 and BRCA2 mutation carriers and sporadic breast tumors. Int. J. 
Cancer 119, 1052-1060 (2006). 
 17.      Tirkkonen,M. et al. Distinct somatic genetic changes associated with tumor 
progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res. 57, 
1222-1227 (1997). 
 18.      Molist,R., Remvikos,Y., Dutrillaux,B., & Muleris,M. Characterization of a new 
cytogenetic subtype of ductal breast carcinomas. Oncogene 23, 5986-5993 (2004). 
 19.      Teixeira,M.R., Pandis,N., & Heim,S. Cytogenetic clues to breast 
carcinogenesis. Genes Chromosomes. Cancer 33, 1-16 (2002). 
 20.      Letessier,A. et al. Frequency, prognostic impact, and subtype association of 
8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. BMC. 
Cancer 6, 245 (2006). 
 21.      Paterson,A.L. et al. Co-amplification of 8p12 and 11q13 in breast cancers is not 
the result of a single genomic event. Genes Chromosomes. Cancer 46, 427-439 
(2007). 
 22.      Reis-Filho,J.S. et al. Cyclin D1 protein overexpression and CCND1 
amplification in breast carcinomas: an immunohistochemical and chromogenic in situ 
hybridisation analysis. Mod. Pathol. 19, 999-1009 (2006). 
 23.      Loi,S. et al. Gene expression profiling identifies activated growth factor 
signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer. 
BMC. Med. Genomics 2, 37 (2009). 
 24.      Sieuwerts,A.M. et al. Anti-epithelial cell adhesion molecule antibodies and the 
detection of circulating normal-like breast tumor cells. J. Natl. Cancer Inst. 101, 61-
66 (2009). 
 25.      Sorlie,T. et al. Gene expression patterns of breast carcinomas distinguish tumor 
subclasses with clinical implications. Proc. Natl. Acad. Sci. U. S. A 98, 10869-10874 
(2001). 
 26.      Tsarouha,H. et al. Karyotypic evolution in breast carcinomas with i(1)(q10) and 
der(1;16)(q10;p10) as the primary chromosome abnormality. Cancer Genet. 
Cytogenet. 113, 156-161 (1999). 
 17
 27.      Buerger,H. et al. Ductal invasive G2 and G3 carcinomas of the breast are the 
end stages of at least two different lines of genetic evolution. J. Pathol. 194, 165-170 
(2001). 
 28.      Korsching,E. et al. Deciphering a subgroup of breast carcinomas with putative 
progression of grade during carcinogenesis revealed by comparative genomic 
hybridisation (CGH) and immunohistochemistry. Br. J. Cancer 90, 1422-1428 
(2004). 
 29.      Abdel-Fatah,T.M. et al. Morphologic and molecular evolutionary pathways of 
low nuclear grade invasive breast cancers and their putative precursor lesions: further 
evidence to support the concept of low nuclear grade breast neoplasia family. Am. J. 
Surg. Pathol. 32, 513-523 (2008). 
 30.      Natrajan,R. et al. Loss of 16q in high grade breast cancer is associated with 
estrogen receptor status: Evidence for progression in tumors with a luminal 
phenotype? Genes Chromosomes. Cancer 48, 351-365 (2009). 
 31.      Rennstam,K., Baldetorp,B., Kytola,S., Tanner,M., & Isola,J. Chromosomal 
rearrangements and oncogene amplification precede aneuploidization in the genetic 
evolution of breast cancer. Cancer Res. 61, 1214-1219 (2001). 
 32.      Courjal,F. et al. Mapping of DNA amplifications at 15 chromosomal 
localizations in 1875 breast tumors: definition of phenotypic groups. Cancer Res. 57, 
4360-4367 (1997). 
 33.      Dontu,G., El-Ashry,D., & Wicha,M.S. Breast cancer, stem/progenitor cells and 
the estrogen receptor. Trends Endocrinol. Metab 15, 193-197 (2004). 
 34.      Polyak,K. Breast cancer: origins and evolution. J. Clin. Invest 117, 3155-3163 
(2007). 
 35.      Sims,A.H., Howell,A., Howell,S.J., & Clarke,R.B. Origins of breast cancer 
subtypes and therapeutic implications. Nat. Clin. Pract. Oncol. 4, 516-525 (2007). 
 36.      Kao,J. et al. Molecular profiling of breast cancer cell lines defines relevant 
tumor models and provides a resource for cancer gene discovery. PLoS. ONE. 4, 
e6146 (2009). 
 37.      Neve,R.M. et al. A collection of breast cancer cell lines for the study of 
functionally distinct cancer subtypes. Cancer Cell 10, 515-527 (2006). 
 38.      Teschendorff,A.E., Miremadi,A., Pinder,S.E., Ellis,I.O., & Caldas,C. An 
immune response gene expression module identifies a good prognosis subtype in 
estrogen receptor negative breast cancer. Genome Biol. 8, R157 (2007). 
 39.      Lim,E. et al. Aberrant luminal progenitors as the candidate target population for 
basal tumor development in BRCA1 mutation carriers. Nat. Med. 15, 907-913 (2009). 
 18
 40.      McClintock,B. The Behavior in Successive Nuclear Divisions of a Chromosome 
Broken at Meiosis. Proc. Natl. Acad. Sci. U. S. A 25, 405-416 (1939). 
 41.      McClintock,B. The Stability of Broken Ends of Chromosomes in Zea Mays. 
Genetics 26, 234-282 (1941). 
 42.      Iakovlev,V.V. et al. Genomic differences between pure ductal carcinoma in situ 
of the breast and that associated with invasive disease: a calibrated aCGH study. Clin. 
Cancer Res. 14, 4446-4454 (2008). 
 43.      Langerod,A. et al. TP53 mutation status and gene expression profiles are 
powerful prognostic markers of breast cancer. Breast Cancer Res. 9, R30 (2007). 
 44.      Naume,B. et al. Presence of bone marrow micrometastasis is associated with 
different recurrence risk within molecular subtypes of breast cancer. Mol. Oncol. 1, 
160-171 (2007). 
 45.      Lucito,R. et al. Representational oligonucleotide microarray analysis: a high-
resolution method to detect genome copy number variation. Genome Res. 13, 2291-
2305 (2003). 
 46.      Barrett,M.T. et al. Comparative genomic hybridization using oligonucleotide 
microarrays and total genomic DNA. Proc. Natl. Acad. Sci. U. S. A 101, 17765-17770 
(2004). 
 47.      van den Ijssen et al. Human and mouse oligonucleotide-based array CGH. 
Nucleic Acids Res. 33, e192 (2005). 
 48.      R Development Core Team (2009). R: A language and environment for 
statistical computing(R Foundation for Statistical Computing, 
Vienna, Austria.,2009). 
 49.      Gentleman,R.C. et al. Bioconductor: open software development for 
computational biology and bioinformatics. Genome Biol. 5, R80 (2004). 
 
 
  





Supplementary Table 1: Demographic data for the four cohorts 
 
  MicMa WZ Ull Caldas 
  no=125 no=141 no=167 n=162 
    
cases (% of 
available cases) 
cases (% of 
available cases) 
cases (% of 
available cases) 
cases (% of 
available cases) 
   
Age (mean, min-max) 61 (33-93) 53 (31-82) 63 (28-90) 57 (32-71)
   
Histologic type   
 IDC 98 (78%) 124 (88%) 110 (67%) 
 ILC 24 (19%) 11 (8%) 40 (25%) 
 Others 2 (2%) 4 (3%) 11 (7%) 
 DCIS 1 (1%) 2 (1%) 2 (1%) 
 Not available 0 0 4/167 (2%) 162/162 (100%)
   
Histologic grade   
 Grade I 14 (12%) 11 (11%) 11 (7%) 37 (23%)
 Grade II 60 (50%) 23 (22%) 110 (67%) 55 (34%)
 Grade III 47 (39%) 70 (67%) 43 (26%) 68 (43%)
 Not available 4/125 (3%) 37/141 (26%) 3/167 (2%) 2/162 (1%)
   
ER status    
 Positive 75 (60%) 92 (79%) 86 (57%) 107 (66%)
 Negative 49 (40%) 25 (21%) 65 (43%) 54 (34%)
 Not available 1/125 (1%) 24/141 (17%) 16/167 (10%) 1/162 (1%)
PgR status    
 Positive 58 (48%) 98 (59%) 
 Negative 64 (52%) 66 (40%) 
 Not available 1/125 (1%) 141/141 (100%) 3/167 (2%) 162/162 (100%)
HER2 FISH status    
 
HER2/cent17 
2 84 (82%)  
 
HER2/cent17 
>2 19 (18%)  
 Not available 22/125 (18%) 141/141 (100%) 167/167(100%) 162/162 (100%)
TP53 status    
 TP53 wt 83 (66%) 124 (74%) 
 TP53 mut 42 (34%) 43 (26%) 
 Not available 0/125 (0%) 141/141 (100%) 0/167 (0%) 162/162 (100%)
   
Tumor size   
 T1 52 (43%) 71 (51%) 57 (35%) 113 (71%)
 T2 57 (47%) 65 (47%) 86 (53%) 47 (29%)
 T3 8 (7%) 2 (2%) 12 (8%) 0
 T4 4 (3%) 0 6 (4%) 0
 Not available 4/125 (3%) 3/141 (2%) 6/167 (3%) 2/162 (1%)
   
Node status   
 Node negative 51 (44%) 69 (49%) 73 (51%) 109 (69%)
 Node positive 64 (56%) 71 (51%) 70 (49%) 49 (31%)
 Not available 10/125 (8%) 1/141 (1%) 24/167 (14%) 4/162 (3%)
Ploidy 
Diploid 41 (41%) 100 (71%)
Aneuploid 60 (59%) 41 (29%)
 Not available 24/125 (19%) 0/141 (0%) 167/167 (100%) 162/162 (100%)
   
Expression class   
 Luminal A 49 (43%) 34 (47%) 54 (48%)
 Luminal B 14 (12%) 6 (8%) 13 (12%)
 erbB2+ 19 (17%) 12 (16%) 14 (13%)
 Basal-like 14 (12%) 13 (18%) 19 (17%)
 Normal-like 14 (12%) 8 (11%) 12 (11%)
 Unclassified 3 (3%) 0 0
 Not available 12/125 (10%) 141/141 (100%) 94/167 (56%) 50/162 (31%)
Treatment, 
chemotherapy  
No 
Chemotherapy 48 (40%) 139 (84%) 154 (96%)
Chemotherapy 71 (60%) 26 (16%) 6 (4%)
 Not available 6/125 (5%) 141/141 (100%) 2/167 (1%) 2/162 (1%)
Treatment, 
Tamoxifen  
No Tamoxifen 63 (53%) 125 (75%) 82 (51%)
Tamoxifen 55 (47%) 41 (25%) 78 (49%)
 Not available 7/125 (6%) 141/141 (100%) 2/167 (1%) 2/162 (1%)
Adjuvant, general  
No adjuvant 48 (40%) 108 (65%) 75 (47%)
Adjuvant 71 (60%) 58 (35%) 86 (53%)
 Not available 6 (5%) 141/141 (100%) 1/167 (1%) 1/162 (1%)
   
   
 
Supplementary Table 2: Distribution between the WAAI groups and CAAI groups in the four cohorts.   
 
 All four cohorts MicMa WZ Ull Caldas
 n=595 n=125 n=141 n=167 n=162 
            
   
WAAI groups¥   
A 204/595 (34%) 49/125 (39%) 38/141 (27%) 66/167 (39%) 51/162 (31%)
B 76/595 (13%) 16/125 (13%) 13/141 (9%) 25/167 (15%) 22/162 (14%)
AB 60/595 (10%) 16/125 (13%) 6/141 (4%) 26/167 (16%) 12/162 (7%)
C 255/595 (43%) 44/125 (35%) 84/141 (60%) 50/167 (30%) 77/162 (48%)
   
CAAI*   
No CAAI 323/595 (54%) 68/125 (54%) 103/141 (73%) 64/167 (38%) 88/162 (54%)
High CAAI 272/595 (46%) 57/125 (46%) 38/141 (27%) 103/167 (62%) 74/162 (46%)
         
 ¥WAAI groups: A: WAAI0.8 on 1q and/or WAAI -0.8 on 16q 
              B: Regional loss of 5q and/or gain of 10p 
              AB: Samples scored by the criteria for both A and B 
              C: Samples scored by neither of the criteria for A and B 
*High CAAI is defined as CAAI0.5. 
 
 
 
Supplementary Table 3: Clinico-pathological characteristics of the four WAAI groups 
 
   
  A B AB C 
  no=204 no=76 no=60 n=255 
(total cases with 
available data)   
cases (% of all 
available A) 
cases (% of all 
available B) 
cases (% of all 
available AB) 
cases (% of all 
available C) 
Chi 
square: 
   
Age (mean, min-max)  
(n=594)  62 (28-90) 57 (33-88) 56 (28-90) 57 (28-93) P<0.001*
   
Histologic type   
n=429 IDC 108/153 (71%) 47/54 (87%) 44/48 (92%) 133/174 (76%)
 ILC 42/153 (27%) 5/54 (9%) 3/48 (6%) 25/174 (14%)
 Others 2/153 (1%) 1/54 (2%) 1/48 (2%) 13/174 (8%) p=0.001
 DCIS 1/153 (1%) 1/54 (2%) 0/48 (0%) 3/174 (2%)
   
Histologic grade    
n=549 Grade I 37/195 (19%) 3/71 (4%) 3/55 (6%) 30/228 (13%)
 Grade II 115/195 (59%) 20/71 (28%) 25/55 (45%) 88/228 (39%) p<0.001
 Grade III 43/195 (22%) 48/71 (68%) 27/55 (49%) 110/228 (48%)
    
ER status    
n=553 Positive 153/187 (82%) 28/74 (38%) 34/59 (58%) 145/233 (62%)
 Negative 34/187 (18%) 46/74 (62%) 25/59 (42%) 88/233 (38%) p<0.001
    
PgR status    
n=286 Positive 70/112 (63%) 15/40(37%) 22/42 (52%) 49/92 (53%)
 Negative 42/112 (37%) 25/40 (63%) 20/42 (48%) 43/92 (47%) p=0.053
    
HER2 status    
n=103 Positive 4/43 (9%) 4/12 (33%) 3/11 (27%) 8/37 (22%)
 Negative 39/43 (91%) 8/12 (67%) 8/11 (72%) 29/37 (78%) p=0.174
    
TP53 status    
n=292 Positive 13/115 (11%) 28/41 (68%) 19/42 (45%) 25/94 (27%)
 Negative 102/115 (89%) 13/41 (32%) 23/42 (55%) 69/94 (73%) p<0.001
   
Tumor size    
n=580 pT1 94/194 (48%) 38/75 (51%) 22/59 (37%) 139/252 (55%)
 pT2 89/194 (46%) 36/75 (48%) 31/59 (53%) 99/252 (39%)
 pT3 8/194 (4%) 1/75 (1%) 4/59 (7%) 9/252 (4%) p=0.275
 pT4 3/194 (2%) 0/75 (0%) 2/59 (3%) 5/252 (2%)
   
Node status   
n=556 Node neg. 96/186 (52%) 41/72 (57%) 24/55 (44%) 141/243 (58%)
 Node pos. 90/186 (48%) 31/72 (43%) 31/55 (56%) 102/243 (42%) n=0.202
    
Expression class    
n=298 Luminal A 86/115 (75%) 2/38 (5%) 10/33 (30%) 39/112 (35%)
 Luminal B 9/115 (8%) 10/38 (26%) 5/33 (15%) 9/112 (8%)
 erbB2+ 6/115 (5%) 7/38 (19%) 2/33 (6%) 30/112 (27%) p<0.001
 Basal-like 1/115 (1%) 18/38 (47%) 14/33 (43%) 13/112 (13%)
 Normal-like 12/115 (10%) 1/38 (3%) 2/33 (6%) 19/112 (17%)
 Unclassified 1/115 (1%) 0/38 (0%) 0 2/112 (2%)
   
Ploidy   
n=242 Diploid 54/80 (68%) 7/25 (28%) 6/18 (33%) 74/119 (62%)
 Aneuploid 26/80 (32%) 18/25 (72%) 12/18 (67%) 45/119 (38%) p=0.001
   
Treatment, 
Tamoxifen   
n=444 No Tam. 94/160 (59%) 42/62 (68%) 31/52 (60%) 103/170 (61%)
 Tam. 66/160 (41%) 20/62 (32%) 21/52 (40%) 67/170 (39%) p=0.666
   
Treatment, CMF   
n=444 No CMF 125/160 (78%) 48/63 (76%) 33/51 (65%) 135/170 (79%)
 CMF 35/160 (22%) 15/63 (24%) 18/51 (35%) 35/170 (21%) p=0.171
   
Adjuvant, general   
n=446 No adjuvant 86/161 (53%) 32/63 (51%) 22/52 (42%) 91/170 (54%) P=0.517
 Adjuvant 65/161 (47%) 31/63 (49%) 30/52 (58%) 79/170 (46%)
          
* Kruskal Wallis 
test   
   
 
Supplementary Table 4: Correlation between  molecular expression subgroups and WAAI groups: 
  A1 A2 B1 B2 AB1 AB2 C1 C2 Total: 
Luminal A 52/65 (80%) 34/50 (68%) 0/14 (0%) 2/24 (8%) 4/12 (33%) 6/21 (29%) 20/61 (33%) 19/51 (37%) 137
Luminal B 2/65 (3%) 7/50 (14%) 3/14 (21%) 7/24 (29%) 1/12 (8%) 4/21 (19%) 4/61 (7%) 5/51 (10%) 33
erbB2+ 2/65 (3%) 4/50 (8%) 1/14 (7%) 6/24 (25%) 0/12 (0%) 2/21 (10%) 15/61 (25%) 15/51 (29%) 45
Basal-like 1/65 (2%) 0/50 (0%) 10/14 (71%) 8/24 (33%) 5/12 (42%) 9/21 (42%) 7/61 (11%) 6/51 (12%) 46
Normal-like 8/65 (12%) 4/50 (8%) 0/14 (0%) 1/24 (4%) 2/12 (17%) 0/21 (0%) 14/61 (23%) 5/51 (10%) 34
NC* 0/65 (0%) 1/50 (2%) 0/14 (0%) 0/24 (0%) 0/12 (0%) 0/21 (0%) 1/61 (1%) 1/51 (2%) 3
Total: 65 50 14 24 12 21 61 51 298 
         
 
*NC: samples with low correlation to all five centroids. 
 
Supplementary Figure legends: 
 
Supplementary Figure 1: Validation of CAAI 
Scatter plot of CAAIs for 17q compared to mean HER2 copy number measured by FISH 
(MicMa cohort). The broken lines indicate the selected threshold (CAAI=0.5). Samples 
with CAAI>=0.5 all except one had 4 or more copies of HER2. A few samples had 
increased HER2 copy number but CAAI<0.5. Inspection of the corresponding aCGH 
profile in such cases revealed that increased copy number was due to narrow amplicons 
and not to complex rearrangements of the firestorm type.  
 
Supplementary Figure 2: Arm wise distribution of WAAI 
The box plots showing the arm-wise distribution of WAAI are illustrating the non-
random distribution of positive and negative WAAI scores in the ChinUC, MicMa/WZ 
and Ull cohort. The chromosomes arms are on the x-axis, and the WAAI sores on the y-
axis. The distribution of WAAI is approximately symmetric around zero for most arms, 
but for others, such as 1q, 8q and 16p, WAAI is skewed towards positive values. For 
others, such as 16q and 17q, WAAI is skewed towards negative values. 
 
Supplementary Figure 3: WAAI and centromere close translocation 
a: Plotted aCGH values for chromosome arm 1q and 16q from case WZ061; 
unsegmented data as blue points and PCF values as black line showed whole 
chromosome arm gain of 1q and loss of 16q. This was reflected in the estimated WAAI; 
WAAI= 1.221 for 1q and WAAI= -1.465 for 16q. 
b: Multi gene FISH analyses with five selected probes derived from centromere close 
BAC clones on chr.1 and chr.16 were hybridized to tumor cells (imprint) from WZ061. 
The image at the top show a tumor cell with all fluorescent probes superimposed 
revealing two green signals together, one orange and red and one green and orange (note 
that the probes will never be fused due to the large stretches of heterochromatin around 
the centromere). The illustration at bottom left show the combination of fluorochromes 
observed in nuclei from lymphocytes with non-translocated chr.1 and chr.16. To the right 
the observed combination in the tumor cells demonstrating a translocation and a 
derivative chromosome; der(1;16)(10q;10p) is illustrated. 
 
Supplementary Figure 4: Frequencies of gains and loss in the four cohorts. 
Frequency plots illustrating the percentage of samples with gain and loss within each 
cohort (red; gain, green; loss). The WZ cohort is enriched in diploid tumors by selection 
and has fewer events in total than the others, but the dominating alterations such as gains 
on 1q, 8q, 16p and 20q and loss on 6q, 8p, 11q,13, 16q, 17p and 22 is seen in all four 
cohorts.  
 
Supplementary Figure 5: Frequencies of gain and loss of the eight WAAI/CAAI 
defined groups. 
Frequency plots illustrating the percentage of samples with gain and loss within each 
WAAI/CAAI group (red; gain, green; loss). A1 tumors are dominated by gain on 1q and 
16p and loss on 16q. These alterations are frequent in A2 tumors, in addition to gain on 
8q, 17q and 20q and loss on 6q, 8p, 11q, 13 and 17p. B1, B2, AB1 and AB2 tumors have 
almost similar patterns of gain and loss where almost all chromosomes are affected, a 
pattern very dissimilar from aberrations in A1 and A2 tumors. C1 tumors have few 
alterations, with gain of 8q dominating. This is the most frequent aberration in C2 tumors 
as well, followed by gain on 1q, 17q and 20q. 
 
Supplementary Figure 6: Frequencies of WAAI in the WAAI/CAAI groups. 
Top: Bar plots illustrating the mean number of altered arms, either gain or loss 
(WAAI0.8 or WAAI -0.8) for each WAAI/CAAI group.  C tumors had fewest 
alterations, and this persisted even if we omitted all cases without any alterations (‘flat’ 
aCGH profiles). A and B tumors had intermediate number of arms altered, with slightly 
more in the latter group. AB tumors had the highest mean value of altered whole arms. In 
all four groups more arms were altered in the tumors with high CAAI on one arm or 
more. 
Middle: Bar plots illustrating the mean number of gained arms (WAAI0.8) for each 
WAAI/CAAI group. The same tendency reflected by the total number of alterations was 
seen for gains alone.  
Bottom: Bar plots illustrating the mean number of lost arms (WAAI -0.8) for each 
WAAI/CAAI group. In contrast to gains, the WAAI/CAAI groups seemed to have almost 
equal mean number of arms altered. This illustrate that the B1 group was dominated by 
tumors with losses, and that the total increase in altered arms seen in samples with high 
CAAI compared to those with low CAAI mainly was due to gains and not losses.   
 
Supplementary Figure 7: Chromosome wise frequencies of WAAI in the 
WAAI/CAAI groups. 
The four plots show the arm wise frequency of samples with whole arm gain or loss as 
measured by WAAI (whole arm gain; WAAI0.8, whole arm loss; WAAI -0.8). The 
plot at the top show A1 and A2 samples (dark and light blue bars), followed by B1 and B2 
samples (dark and bright red), AB1 and AB2 samples (orange and yellow) and at the 
bottom the C1 and C2 samples (dark and light green).The A1 and A2 tumors had the same 
distributions of altered arms, but A2 tumors had more frequent gain of 8q, 16p, 20p and 
20q. B1 tumors were dominated by whole arm losses (such as 17p, 4p, 4q and 5q), while 
B2 tumors had more frequent gain of 8q, 10p16p and 20q.  AB tumors had whole arm 
alterations resembling both the loss and gain pattern of both A and B tumors, with only 
little difference between AB1 and AB2 tumors. C tumors had the fewest numbers of 
whole arm alterations with gain of 8q and 16p and loss of 17p and 22 as the most 
frequent.  
Supplementary Figure 8: Chromosome wise frequencies of CAAI in the 
WAAI/CAAI groups. 
The four plots show the arm wise frequency of samples with complex rearrangements as 
measured by CAAI (CAAI0.5). The plot at the top show A2 samples (light blue bars), 
followed by B2 samples (bright red), AB2 samples (yellow) and at the bottom the C2 
samples (light green). A2 tumors had high CAAI most frequent on 11q, 8p, 17q and 8q, 
B2 tumors had high CAAI on more arms (such 17q, 20q and 8p) while AB2 had a more 
heterogeneous distribution pattern of arms with high CAAI. In C tumors, high CAAI was 
most frequent on 17q. 
 
Supplementary Figure 9: Ploidy measurements and histological grade in the 
WAAI/CAAI groups.   
Top: Bar plot illustrating the distribution of aneuploid and diploid samples in each of the 
eight WAAI/CAAI groups. All groups had both diploid and aneuploid tumors, it was a 
higher percentage of diploids in A and C tumors compared to B and AB, and aneuploid 
tumors were more frequent in all groups with high CAAI compared to the respective 
groups with low CAAI. 
Bottom: Bar plot illustrating the distribution of histological grade in the eight 
WAAI/CAAI groups. Grade 1 tumors were most frequent in A1 and AB1 tumors, and 
rarely found in the other groups. In A tumors, there were a reduced proportion of grade 1 
and grade 2 tumors in A2 compared to A1, the same was seen for the C tumors. The 
highest percentage of grade 3 tumors was found in the B group.  
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